CELL-CYCLE CHECKPOINT GENES

Abstract: This invention relates to a class of checkpoint genes and their polypeptide products which control progression through the cell cycle in eukaryotic cells. In particular this invention relates to Schizosaccharomyces pombe rad3 gene, to its human homologue (ATR) and to their encoded proteins. The invention further relates to assay methods for selecting compounds which modulate the activity of the polypeptide products of these checkpoint genes and the use of the selected compounds in anticancer therapy.

Description: Cel l -cycle checkpoint genes The present invention relates to a class of checkpoint genes which control progression through the cell cycle in eukaryotic cells. Background to the invention. Control of the cell cycle is fundamental to the growth and maintenance of eukaryotic organisms, from yeasts to mammals. Eukaryotic cells have evolved control pathways, termed "checkpoints" which ensure that individual steps of the cell cycle are completed before the next step occurs. In response to DNA damage, cell survival is increased both by direct DNA repair mechanisms and by delaying progression through the cell cycle. Depending on the position of the cell within the cycle at the time of irradiation, DNA damage in mammalian cells can prevent (a) passage from Gl into S phase, (b) progression through S phase or (c) passage from G2 into mitosis. Such checkpoints are thought to prevent deleterious events such as replication of damaged DNA and the segregation of fragmented chromosomes during mitosis (Hartwell and Kastan, 1994). The radS gene of Schizosaccharomyces pombe is required for the checkpoints that respond to DNA damage and replication blocks. Rad3 is a member of the lipid kinase subclass of kinases which possess regions having sequence homology to the lipid kinase domain of the pllO subunit of phosphatidylinositol-3 kinase (PI-3 kinase). This subclass also includes the ATM protein defective in ataxia-telangiectasia patients. Cells from ataxia telangiectasia patients (AT cells) have lost the delay to S phase following irradiation and are said to display radio resistant DNA synthesis (Painter and Young, 1989). AT cells irradiated in S phase accumulate in G2 with lethal damage, presumably as a consequence of attempting to replicate damaged DNA. AT cells irradiated during G2 display a different phenotype: they do not arrest mitosis after DNA damage, and progress through mitosis with damaged DNA (Beamish and Lavin, 1994). Mutations at the A-T locus, to which the ATM gene has been mapped, thus result in disruption of several checkpoints required for an appropriate response to ionising radiation. Other members of this lipid kinase subclass include: Tellp (Greenwell et al. 1985), a gene involved in maintaining proper telomere length in Saccharomyces cerevisiae; Esrlp; Meclp and the product of the Drosophila melanogaster mei-41 checkpoint gene (Hari et al. 1995). Disclosure of the invention. We have analyzed the S. pombe rad3 gene and found that it has a full length amino acid sequence of 2386 amino acids, not the 1070 amino acids described by Seaton et al. 1992. We have determined that this is the direct homologue of S. cerevisiae Esrlp, and that it shares the same overall structure as the ATM gene. The C-teπninal region of the rad3 protein contains a lipid kinase domain, which is required for Rad3 function. We have shown that Rad3 is capable of self association. We have also identified a protein kinase activity associated with Rad3. Further, we have found a human homologue to rad3. This gene, which we have named ATR (ataxia and rad related), displays significantly higher homology to rad3 than it does to the ATM gene. The human ATR cDNA sequence is set out as Seq. ID No. 1. The amino acid sequence of the ORF from nucleotides 80 and 8011 is set out as Seq. ID No. 2. The DNA sequence of the open reading frame (ORF) of rad3 is shown as Seq. ID. No. 3. The 2386 amino acid translation of die gene (nucleotides 585 to 7742 of Seq. ID No. 3) is shown as Seq. ID. No. 4. Accordingly, in a first aspect, the invention provides the ATR protein of Seq. ID. 2 and homologues thereof, polypeptide fragments thereof, as well as antibodies capable of binding the ATR protein or polypeptide fragments thereof. ATR proteins, homologues and fragments thereof are referred to below as polypeptides of the invention. In another aspect, the present invention provides a polynucleotide in substantially isolated form capable of hybridising selectively to Seq. ID No 1 or to the complement (i.e. opposite strand) thereof. Also provided are polynucleotides encoding polypeptides of the invention. Such polynucleotides will be referred to as a polynucleotide of the invention. A polynucleotides of the invention includes DNA of Seq.ID Nos 1 and fragments thereof capable of selectively hybridising to this gene. In a further aspect, the invention provides recombinant vectors carrying a polynucleotide of the invention, including expression vectors, and methods of growing such vectors in a suitable host cell, for example under conditions in which expression of a protein or polypeptide encoded by a sequence of the invention occurs. In an additional aspect, the invention provides kits comprising polynucleotides, polypeptides or antibodies of the invention and methods of using such kits in diagnosing the presence of absence of ATR and its homologues, or variants thereof, including deleterious ATR mutants. The invention further provides assay methods for screening candidate substances for use as compounds for inhibiting or activating ATR activity, or the activity of mutated forms of ATR which are deficient in checkpoint activity. The invention also provides assay methods for screening candidate substances for use as compounds for inhibiting interactions between ATR and other compounds that interact with ATR, including ATR itself. In a related aspect, the invention also provides a polynucleotide sequence of Seq. ID No. 3 in substantially isolated form, and me protein of Seq. ID No. 4 in substantially isolated form, and novel fragments and variants thereof. Detailed description of the invention. A. Polynucleotides. Polynucleotides of the invention may comprise DNA or RNA. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For me purposes of the present invention, it is to be understood diat the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or lifespan of polynucleotides of the invention. Polynucleotides of the invention capable of selectively hybridizing to the DNA of Seq. ID No. 1 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the corresponding DNA of Seq. ID No. 1 over a region of at least 20, preferably at least 25 or 30, for instance at least 40, 60 or 100 or more contiguous nucleotides. It is to be understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides of the invention to reflect the codon usage of any particular host organism in which the polypeptides of the invention are to be expressed. Any combination of the above mentioned degrees of homology and minimum sizes may be used to defme polynucleotides of the invention, with the more stringent combinations (i.e. higher homology over longer lengths) being preferred. Thus for example a polynucleotide which is at least 80% homologous over 25, preferably 30 nucleotides forms one aspect ofthe invention, as does a polynucleotide which is at least 90% homologous over 40 nucleotides. Polynucleotides of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein. Polynucleotides such as a DNA polynucleotide and primers according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques. In general, primers will be produced by synthetic means, involving a step wise manufacture of me desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art. Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15-30 nucleotides) to a region of the ATR gene which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from a human cell (e.g. a dividing cell such as a peripheral blood leukocyte), performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector. Such techniques may be used to obtain all or part of the ATR sequence described herein. Genomic clones containing the ATR gene and its introns and promoter regions may also be obtained in an analogous manner, starting with genomic DNA from a human cell, e.g. a liver cell. Although in general the techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook et al. (Molecular Cloning: A Laboratory Manual, 1989). Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways. Other human allelic variants of the ATR sequence described herein may be obtained for example by probing genomic DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other animal, particularly mammalian (e.g. mice, rats or rabbits), more particularly primate, homologues of ATR may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridizing to Seq. ID No. 1. Such sequences may be obtained by probing cDNA libraries made from dividing cells or tissues or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of Seq. ID. 1 under conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60oQ. Allelic variants and species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences. Conserved sequences can be predicted from aligning the ATR amino acid sequence witii that of rad3. The primers will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences. Alternatively, such polynucleotides may be obtained by site directed mutagenesis of the ATR sequences or allelic variants thereof. This may be useful where for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides. Further changes may be desirable to represent particular coding changes found in ATR which give rise to mutant ATR genes which have lost the checkpoint function. Probes based on such changes can be used as diagnostic probes to detect such ATR mutants. The invention further provides double stranded polynucleotides comprising a polynucleotide of the invention and its complement. Polynucleotides or primers of the invention may carry a revealing label. Suitable labels include radioisotopes such as 32 P or 35 S, enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides or primers of the invention and may be detected using by techniques known per se. Polynucleotides or primers of the invention or fragments thereof labelled or unlabelled may be used by a person skilled in the aπ in nucleic acid-based tests for detecting or sequencing ATR in the human or animal body. Such tests for detecting generally comprise bringing a human or animal body sample con ining DNA or RNA into contact with a probe comprising a polynucleotide or primer of the invention under hybridizing conditions and detecting any duplex formed between the probe and nucleic acid in the sample. Such detection may be achieved using techniques such as PCR or by immobilizing the probe on a solid support, removing nucleic acid in the sample which is not hybridized to the probe, and men detecting nucleic acid which has hybridized to the probe. Alternatively, the sample nucleic acid may be immobilized on a solid support, and the amount of probe bound to such a support can be detected. Suitable assay methods of this any other formats can be found in for example WO89/03891 and WO90/13667. Tests for sequencing ATR include bringing a human or animal body sample containing target DNA or RNA into contact with a probe comprising a polynucleotide or primer of the invention under hybridizing conditions and determining the sequence by, for example the Sanger dideoxy chain termination method (see Sambrook et al.). Such a method generally comprises elongating, in the presence of suitable reagents, the primer by synthesis of a strand complementary to the target DNA or RNA and selectively terminating the elongation reaction at one or more of an A, C, G or T/U residue; allowing strand elongation and termination reaction to occur; separating out according to size the elongated products to determine the sequence of the nucleotides at which selective termination has occurred. Suitable reagents include a DNA polymerase enzyme, the deoxynucleotides dATP, dCTP, dGTP and dTTP, a buffer and ATP. Dideoxynucleotides are used for selective termination. Tests for detecting or sequencing ATR in the human or animal body may be used to determine ATR sequences within cells in individuals who have, or are suspected to have, an altered ATR gene sequence, for example within cancer cells including leukaemic cells and solid tumours such as breast, ovary, lung, colon, pancreas, testes, liver, brain, muscle and bone tumours. In addition, the discovery of ATR will allow the role of this gene in hereditary diseases to be investigated, in a manner analogous to the ATM gene. In general, this will involve establishing the status of ATR (e.g using PCR sequence analysis) in cells derived from patients with diseases that may be connected with damage to replicating cells, e.g. familial predisposition to cancer, chromosome breakage or instability phenotype or repair-damage sensitivity phenotype. The probes of the invention may conveniently be packaged in the form of a test kit in a suitable container. In such kits the probe may be bound to a solid support where the assay format for which the kit is designed requires such binding. The kit may also contain suitable reagents for treating the sample to be probed, hybridizing the probe to nucleic acid in the sample, control reagents, instructions, and the like. The present invention also provides polynucleotides encoding the polypeptides of the invention described below. Because such polynucleotides will be useful as sequences for recombinant production of polypeptides of the invention, it is not necessary for them to be selectively hybridizable to the sequence Seq. ID No. 1, although this will generally be desirable. Otherwise, such polynucleotides may be labelled, used, and made as described above if desired. Polypeptides of the invention are described below. Particularly preferred polynucleotides ofthe invention are those derived from the lipid kinase domain of ATR, its allelic variants and species homologues. The lipid kinase domain is represented by nucleotides 7054 to 8011 of Seq. ID. 1. Polynucleotides of the invention which comprise this domain are particularly preferred. The term "lipid kinase domain" refers to a domain which has homology to other known lipid kinases, in particular the pllO subunit of PI-3 kinase, as determined by sequence alignments. Other preferred polynucleotides of the invention those which comprise nucleotides encoding amino acids 181 to 302 of Seq. ID No. 2 (nucleotides 620 to 985 of Seq. ID No. 1), which is believed to be a leucine zipper region, a putative site of protein-protein interaction, and amino acids 1358 to 1366 (nucleotides 4151 to 4177), which is also conserved. In an additional aspect, polynucleotides of the invention include those of Seq. ID No. 3 and fragments thereof capable of selectively hybridizing to this sequence other than the fragment consisting of nucleotides 2482 to 6599 in which the following changes have been made: Deletion of residues 2499, 2501, 2507 & 2509; insertion of C between 5918/5919. Particularly preferred fragments include those comprising residues 6826 to 7334 (the lipid kinase domain) and the leucine zipper regions 1476 to 1625 and 2310 to 2357. Additionally, the fragment comprising the conserved region 3891 to 3917 is preferred. Such polypeptides and fragments may be made and used as described above. B. Polypeptides. Polypeptides of the invention include polypeptides in substantially isolated form which comprise the sequence set out in Seq ID No. 2. Polypeptides further include variants of such sequences, including naturally occurring allelic variants and synthetic variants which are substantially homologous to said polypeptides. In this context, substantial homology is regarded as a sequence which has at least 70%, e.g. 80% or 90% amino acid homology (identity) over 30 amino acids with the sequence of Seq. ID No. 2 except for the lipid kinase domain and C-terminal portion (residues 2326 to 2644) where substantial homology is regarded as at least 80% homology, preferably 90% homology (identity) over 50 amino acids. Polypeptides also include other those encoding ATR homologues from other species including animals such as mammals (e.g. mice, rats or rabbits), especially primates, and variants thereof as defined above. Polypeptides of the invention also include fragments of the above mentioned full length polypeptides and variants thereof, including fragments of the sequence set out in Seq. ID No. 2. Preferred fragments include those which include an epitope, especially an epitope. Suitable fragments will be at least about 5, e.g. 10, 12, 15 or 20 amino acids in size. Polypeptide fragments of the ATR protein and allelic and species variants thereof may contain one or more (e.g. 2, 3, 5, or 10) substitutions, deletions or insertions, including conserved substitutions. Conserved substitutions may be made according to the following table indicates conservative substitutions, where amino acids on the same block in the second column and preferably in the same line in the third column may be substituted for each other: - 10 Variants of the polypeptides of the invention may also comprise polypeptides wherein one or more of the specified (i.e., namrally encoded) amino acids is deleted or replaced or wherein one or more nonspecified amino acids are added: (1) without loss of the kinase activity specific to the polypeptides of the invention; or (2) with disablement of the kinase activity specific to the polypeptides of the invention; or (3) with disablement of the ability to interact with members or regulators of the cell cycle checkpoint pathway. Epitopes may be determined either by techniques such as peptide scanning techniques as described by Geysen et al. Mol. Immunol., 23; 709-715 (1986). Polypeptides of the invention may be in a substantially isolated form. It will be understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is a polypeptide of the invention. Polypeptides of the invention may be modified for example by the addition of Histidine residues to assist their purification or by the addition of a signal sequence to promote their secretion from a cell. A polypeptide of the invention may be labelled wim a revealing label. The revealing label may be any suitable label which allows the polypeptide to be detected. Suitable labels include radioisotopes, e.g. 125 I, enzymes, antibodies, polynucleotides and linkers such as biotin. Labelled polypeptides of the invention may be used in diagnostic procedures such as immunoassays in order to determine the amount of a polypeptide of the invention in a sample. Polypeptides or labelled polypeptides of the invention may also be used in serological or cell mediated immune assays for the detection of immune reactivity to said polypeptides in animals and humans using standard protocols. A polypeptide or labelled polypeptide of the invention or fragment thereof may also be fixed to a solid phase, for example the surface of an immunoassay well or dipstick. Such labelled and/or immobilized polypeptides may be packaged into kits in a suitable container along with suitable reagents, controls, instructions and d e like. Such polypeptides and kits may be used in methods of detection of antibodies to the ATR protein or its allelic or species variants by immunoassay. Immunoassay methods are well known in the aπ and will generally comprise: (a) providing a polypeptide comprising an epitope bindable by an antibody against said protein; (b) incubating a biological sample wim said polypeptide under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whemer antibody-antigen complex comprising said polypeptide is formed. Polypeptides of the invention may be may by synmetic means (e.g. as described by Geysen et al.) or recombinantly, as described below. Particularly preferred polypeptides of me invention include those spanning or wid in the lipid kinase domain, namely from amino acids 2326 to 2644 of Seq. ID. 2. or sequences substantially homologous thereto. Fragments as defined above from this region are particularly preferred. The polypeptides and fragments thereof may contain amino acid alterations as defmed above, including substitutions at one or more of positions 2475, 2480 and 2494, which correspond to me positions of me rad3 substitutions described in the examples below. Preferred substitutions include D2475A, N2480K and D2494E. Polypeptides of the invention may be used in in vitro or in vivo cell culture systems to study the role of ATR as a checkpoint gene. For example, truncated or modified (e.g. modified in the lipid kinase domain) ATRs may be introduced into a cell to disrupt the normal checkpoint functions which occur in the cell. The polypeptides of the invention may be introduced into the cell by in situ expression of the polypeptide from a recombinant expression vector (see below). The expression vector optionally carries an inducible promoter to control the expression of the polypeptide. The use of mammalian host cells is expected to provide for such post-translational modifications (e.g., myristolation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention. Such cell culture systems in which polypeptide of the invention are expressed may be used in assay systems to identify candidate substances which interfere or enhance checkpoint functions in the cell (see below). In an additional aspect, polypeptides of the invention include the protein of Seq. ID No. 4 and fragments thereof from the region other than the fragment consisting of amino acids 713 to 1778. Particularly preferred fragments include those comprising residues 2082 to 2386 (the lipid kinase domain) and the leucine zipper regions 298 to 347 and 576 to 591. Additionally, the fragment comprising the conserved region 1103 to 1111 is preferred. Such polypeptides and fragments may be made and used as described above. The invention also provides polypeptides substantially homologous to the protein of Seq. ID No. 4, and fragments thereof. In this context, substantial homology is regarded as a sequence which has at least 70%, e.g. 80% or 90% amino acid homology (identity) over 30 amino acids with the sequence of Seq. ID No. 4 except for the lipid kinase domain and C-terminal poπion (residues 2082 to 2386) where substantial homology is regarded as at least 80%, preferably at least 90% homology (identity) over 50 amino acids. C. Vectors. Polynucleotides of the invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide ofthe invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells are described below in connection with expression vectors. P. Expression Vectors. Preferably, a polynucleotide of the invention in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible wim the control sequences. Such vectors may be transformed into a suitable host cell as described above to provide for expression of a polypeptide of me invention. Thus, in a further aspect the invention provides a process for preparing polypeptides according to the invention which comprises cultivating a host cell transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding die polypeptides, and recovering e expressed polypeptides. The vectors may be for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell. The vector may also be adapted to be used in vivo, for example in a method of gene tiierapy. A further embodiment of the invention provides host cells transformed or transfected with the vectors for the replication and expression of polynucleotides of the invention. The cells will be chosen to be compatible with the said vector and may for example be bacterial, yeast, insect or mammalian. Polynucleotides according to the invention may also be inserted into the vectors described above in an antisense orientation in order to provide for the production of antisense RNA. Antisense RNA or other antisense polynucleotides may also be produced by synthetic means. Such antisense polynucleotides may be used in a method of controlling the levels of ATR or its variants or species homologues. Promoters and other expression regulation signals may be selected to be compatible wim the host cell for which the expression vector is designed. For example, yeast promoters include S. cerevisiae GAL4 and ADH promoters, S. pombe nmtl and adh promoter. Mammalian promoters include the metallothionein promoter which is can be included in response to heavy metals such as cadmium. Viral promoters such as the SV40 large T antigen promoter or adenovirus promoters may also be used. All these promoters are readily available in the art. E. Antibodies. The invention also provides monoclonal or polyclonal antibodies to polypeptides of the invention or fragments thereof. The invention further provides a process for the production of monoclonal or polyclonal antibodies to polypeptides of the invention. Monoclonal antibodies may be prepared by conventional hybridoma technology using the polypeptides of the invention or peptide fragments mereof, as immunogens. Polyclonal antibodies may also be prepared by conventional means which comprise inoculating a host animal, for example a rat or a rabbit, with a polypeptide of die invention or peptide fragment thereof and recovering immune serum. In order that such antibodies may be made, the invention also provides polypeptides of the invention or fragments thereof haptenised to another polypeptide for use as immunogens in animals or humans. Preferred antibodies of d e invention will be capable of selectively binding the human ATR protein, that is with an affinity at least 10 fold, preferably at least 100 fold that of the rad3 protein. Such antibodies can be obtained by routine experimentation, e.g. selecting regions of ATR protein with sequences different from the corresponding regions of rad3, making peptides comprising such sequences and using such peptides as immunogens. Following production of antibodies die binding of said antibodies may be determined. Preferred antibodies of the invention include those capable of selectively binding the lipid kinase domain (as defmed above) of the human ATR protein. In addition, antibodies which are capable of binding the human and yeast (S. pombe) lipid kinase domains with similar affinity, but not to the domains of the ATM family of proteins foπn a further aspect of the invention. Such antibodies may be raised against peptides from the lipid kinase domains which correspond to regions found to be identical, or substantially identical, in the yeast and human genes. For me purposes of this invention, the term "antibody", unless specified to me contrary, includes fragments of whole antibodies which retain their binding activity for a tumour target antigen. Such fragments include Fv, F(ab') and F(ab') 2 fragments, as well as single chain antibodies. Furthermore, me antibodies and fragments mereof may be humanised antibodies, eg. as described in EP-A-239400. Antibodies may be used in memod of detecting polypeptides of the invention present in biological samples by a method which comprises: (a) providing an antibody of me invention; (b) incubating a biological sample with said antibody under conditions which allow for me formation of an antibody-antigen complex; and (c) detennining whe er antibody-antigen complex comprising said antibody is formed. Suitable samples include extracts from dividing cells, e.g leukocytes or cancer cells including leukaemic cells and solid tumours such as breast, ovary, lung, colon, pancreas, testes, liver, brain, muscle and bone tumours. Antibodies of the invention may be bound to a solid support and/or packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like. F. Assays. Abrogating cell cycle checkpoints is a potential strategy for developing or designing drugs for anti-cancer merapy, bom as a novel treatment as such and as pan of a combination merapy to enhance the specific toxicity of cuπent chemotherapeutic agents. For example alkylating agents such as nitrogen mustards are used a chemotherapeutic agents which damage DNA in rapidly dividing cells, leading to cell deatii. The toxicity of such agents may be lessened by DNA repair and checkpoint mechanisms. Abrogating such mechanisms will thus enhance the effectiveness of therapeutic compounds designed to damage DNA. Abrogation ofthe ATR checkpoint will be especially useful where tumour cells have lost otiier checkpoint or damage response genes, since these other genes may be able to complement the loss of ATR function in non tumour cells, leading to an even greater enhancement in the effectiveness of the chemotherapeutic agent. The lipid kinase activity of ATR is a target for developing anti-cancer compounds, since the results presented in the following examples indicate that the kinase domain is required for ATR function. Thus the present invention provides an assay method for screening candidate substances for anti-cancer therapy which comprises: (a) providing a polypeptide of me invention which retains lipid kinase activity and a substrate for said kinase, under conditions and with reagents such diat the kinase activity will act upon the substrate; (b) bringing said polypeptide and substrate into contact wim a candidate substance; (c) measuring the degree of decrease in the kinase activity of the polypeptide; and (d) selecting a candidate substance which provides a decrease in activity. The assay may be carried out in vitro, for example in the wells of a microtitre dish. Such a format may be readily adapted for automation, allowing large numbers of candidate substances to be screened. The substrate may be a protein or lipid substrate of natural or synmetic origin upon which the polypeptide of the invention will act. Usually, me polypeptide of the invention will phosphorylate the substrate. Any suitable format for the assay may be used by those of skill in the an of throughput assays. Typically, the polypeptide of the invention which retains lipid kinase activity will be bound to a solid support in the presence of a substrate and cellular and other components which are usually required for activity. Labelled phosphate and a candidate substance will be added to d e mixture simultaneously or sequentially in either order. After a suitable reaction time (usually a few minutes but in any event enough for phosphorylation of the substrate in the absence of candidate substance to occur) d e amount of free phosphate is determined, e.g. by precipitation of phosphate. Candidate substances which inhibit kinase activity will inhibit the incorporation of free phosphate into me substrate and thus where free phosphate is found this is indicative of inhibition. Other assay formats may be used by mose skilled in die an. The candidate substances may be used in an initial screen in batches of for example 10 compounds per reaction, and the compounds of those batches which show inhibition tested individually. Suitable candidate substances include peptides, especially of from about 5 to 20 amino acids in size, based on me sequence of the kinase domain, or variants of such peptides in which one or more residues have been substituted as described above. Peptides from panels of peptides comprising random sequences or sequences which have been varied consistently to provide a maximally diverse panel of peptides may be used. Further candidate substances include kinase inhibitors which are small molecules such as cyclosporin-like and staurosporin- like compounds, or otiier compounds commercially available in panels of small molecule inhibitors. Candidate substances which show activity in in vitro screens such as the above can men be tested in in vivo systems, such as yeast or mammalian cells which will be exposed to the inhibitor and tested for checkpoint activity. We have also shown that Rad3 possesses protein kinase activity. Target substrates of Rad3 protein kinase activity may be identified by incorporating test compounds in assays for kinase activity. Rad3 protein is resuspended in kinase buffer and incubated ei er in the presence of absence of the test compound (e.g., casein, histone HI, or appropriate substrate peptide). Moles of phosphate transfeπed by the kinase to the test compound are measured by autoradiography or scintillation counting. Transfer of phosphate to the test compound is indicative ύiat the test compound is a substrate of the kinase. Agents that modulate Rad3/ATR lipid kinase or Rad 3 protein kinase activity may be identified by incubating a test compound and Rad3/ATR immunopurified from cells namrally expressing Rad3/ATR, widi Rad3/ATR obtained from recombinant procaryotic or eukaryotic cells expressing me enzyme, or wim purified Rad3/ATR, and men determining me effect of the test compound on Rad3/ATR activity. The activity of the Rad3/ATR lipid kinase or Rad3 protein kinase domains can be measured by determining the moles of 32 P-phosphate transfeπed by me kinase from gamma- 32 -P-ATP to either itself (autophosphorylation) or to an exogenous substrate such as a lipid or protein. The amount of phosphate incorporated into the substrate is measured by scintillation counting or autoradiography. An increase in me moles of phosphate transferred to d e substrate in the presence of me test compound compared to d e moles of phosphate transferred to the substrate in the absence of the test compound indicates that the test compound is an activator of said kinase activity. Conversely, a decrease in the moles of phosphate transfeπed to die substrate in presence of the test compound compared to the moles of phosphate transfeπed to the substrate in the absence of the test compound indicates mat the modulator is an inhibitor of said kinase activity. In a presently prefeπed assay, a Rad3/ATR antibody linked to agarose beads is incubated wim a cell lysate prepared from host cells expressing Rad3/ATR. The beads are washed to remove proteins binding nonspecifically to the beads and me beads are then resuspended in a kinase buffer (such as 25 mM K-HEPES pH 7.7, 50 mM potassium chloride, 10 mM magnesium chloride, 0.1 % Nonidet-P-40, 20% glycerol. 1 mM DTT). The reaction is initiated by me addition of 100 μM gamma- 3 P-ATP (4 Ci/mM) and an exogenous substrate such as lipid or peptide, and d e reaction is carried out at 30°C for 10 minutes. The activity of the kinase is measured by determining the moles of 32 P-phosphate transfeπed eimer to me kinase itself or the added substrate. In a prefeπed embodiment the host cells lack endogenous Rad3/ATR kinase activity. The selectivity of a compound mat modulates me lipid kinase activity of Rad3/ATR can be evaluated by comparing its activity on Rad3/ATR to its activity on, for example, other known phosphatidylinositol-3 (PI-3)-related kinases. The combination of the recombinant Rad3/ATR products of me invention widi otfier recombinant PI-3-related kinase products in a series of independent assays provides a system for developing selective modulators of Rad3/ATR kinase activity. Similarly, the selectivity of a compound that modulates the protein kinase activity of Rad3 may be determined with reference to other protein kinases, for example me DNA dependent protein kinase or ATM. In addition, the demonstration diat the rad mutant rad.D2249E (see Examples) can act as a dominant negative mutant indicates involvement in one or more protein complexes, and such complexes themselves can be targeted for therapeutic intervention. We have shown, for example, that Rad3 can both self associate and associate with ATR. It is therefore likely that Rod/ TR function as multimeric molecules. Mutant yeast rad or human ATR genes, or derivatives thereof which also lack rad/ ATR activity may be introduced into cells to act as dominant negative mutants. Thus for example if expression of a dominant negative mutant (e.g. ATR D2475A, N2480K or D2494E) in a tumour cell leads to enhanced radiation sensitivity this indicates d at the native ATR is still functioning and thus a target for therapeutic agents. Interacting proteins including components of multimeric protein complexes involving Rad3 or ATR may be identified by me following assays. A first assay contemplated by the invention is a two-hybrid screen. The two-hybrid system was developed in yeast (Chien et al. (1991)) and is based on functional in vivo reconstitution of a transcription factor which activates a reporter gene. Specifically, a polynucleotide encoding a protein that interacts wim Rad3/ATR is isolated by: transforming or transfecting appropriate host cells with a DNA construct comprising a reporter gene under me control of a promoter regulated by a transcription factor having DNA a binding domain and an activating domain; expressing in me host cells a first hybrid DNA sequence encoding a first fusion of part or all of Rad3/ATR and either the DNA binding domain or the activating domain of the transcription factor; expressing in the host cell a library of second hybrid DNA sequences encoding second fusion of part or all putative Rad3/ATR binding proteins and the DNA binding domain or activating domain of the transcription factor which is not incorporated in the first fusion; detecting binding of an Rad3/ATR interacting protein to Rad3/ATR in a particular host cell by detecting me production of reporter gene product in the host cell; and isolating second hybrid DNA sequences encoding the interacting protein from the particular host cell. Presently prefeπed for use in the assay are a lexA promoter to drive expression of me reporter gene, the lacZ reporter gene, a transcription factor comprising the lexA DNA binding domain and the GAL4 transactivation domain, and yeast host cells. Other assays for identifying proteins that interact with Rad3 or ATR may involve immobilising Rad3/ATR or a test protein, detectably labelling me noni mobilised binding partner, incubating the binding partners together and determining the amount of label bound. Bound label indicates d at the test protein interacts with Rad3/ATR. Anomer type of assay for identifying Rad3 or ATR interacting proteins involves immobilising Rad3/ATR or a fragment thereof on a solid support coated (or impregnated wim) a fluorescent agent, labelling a test protein wim a compound capable of exciting the fluorescent agent, contacting the immobilised Rad3/ATR wim the labelled test protein, detecting light emission by the fluorescent agent, and identifying interacting proteins as test proteins which result in the emission of light by the fluorescent agent. Alternatively, the putative interacting protein may be immobilised and Rad3/ATR may be labelled in the assay. Compounds diat modulate interaction between Rad3/ATR and omer cellular components may be used in methods of treating cancer. For example, if a particular form of cancer results from a mutation in a gene omer an ATR such as the p53 gene, an agent which inhibits die transcription or me enzymatic activity of ATR and mus the G 2 cell cycle checkpoint may be used to render cancerous cells more susceptible to chemotherapy or radiation merapy. The therapeutic value of such an agent lies in me fact mat cuπent radiation merapy or chemotherapy in most cases does nothing to overcome me ability of the p53 mutant cancerous cell to sense and coπect me DNA damage imposed as a result of the treatment. As a result, a cancer cell can simply repair the DNA damage. Modulating agents of the invention may tiierefore be chemotherapy and radiation adjuvants or may be directly active as chemotherapy drugs themselves. Assays for identifying compounds d at modulate interaction of Rad3/ATR wim omer proteins may involve: transforming or transf ecting appropriate host cells with a DNA construct comprising a reporter gene under the control of a promoter regulated by a transcription factor having a DNA-binding domain and an activating domain; expressing in the host cells a first hybrid DNA sequence encoding a first fusion of part or all of Rad3/ATR and die DNA binding domain or d e activating domain of the transcription factor; expressing in the host cells a second hybrid DNA sequence encoding part or all of a protein mat interacts with Rad3/ATR and die DNA binding domain or activating domain of the transcription factor which is not incorporated in the first fusion; evaluating the effect of a test compound on the interaction between Rad3/ATR and d e interacting protein by detecting binding of me interacting protein to Rad3/ATR in a particular host cell by measuring me production of reporter gene product in the host cell in the presence or absence of the test compound; and identifying modulating compounds as those test compounds altering production of the reported gene product in comparison to production of me reporter gene product in the absence of the modulating compound. Presently prefeπed for use in the assay are a lexA promoter to drive expression of me reporter gene, the lacZ reporter gene, a transcription factor comprising the lexA DNA domain and d e GAL4 transactivation domain, and yeast host cells. Anodier type of assay for identifying compounds diat modulate die interaction between Rad3/ATR and an interacting protein involves immobilising Rad3/ATR or a natural Rad3/ATR interacting protein, detectably labelling the nonimmobilised binding partner, incubating the binding partners togedier and deterrnining the effect of a test compound on me amount of label bound wherein a reduction in die label bound in the present of the test compound compared to die amount of label bound in me absence of the test compound indicates diat the test agent is an inhibitor of Rad3/ATR interaction with the protein. Conversely, an increase in me bound in the presence of d e test compared to me amount label bound in the absence of the compared indicates mat the putative modulator is an activator of Rad3/ATR interaction with the protein. Yet anomer method contemplated by the invention for identifying compounds diat modulate me binding between Rad3/ATR and an interacting protein involves immobilising Rad3/ATR or a fragment thereof on a solid support coated (or impregnated wim) a fluorescent agent, labelling me interacting protein with a compound capable of exciting the fluorescent agent, contacting the immobilised Rad3/ATR wim the labelled interacting protein in the presence and absence of a test compound, detecting light emission by the fluorescent agent, and identifying modulating compounds as mose test compounds that affect the emission of light by the fluorescent agent in comparison to die emission of light by the fluorescent agent in me absence of the test compound. Alternatively, the Rad3/ATR interacting protein may be immobilised and Rad3/ATR may be labelled in the assay. We have shown that Rad3 interacts wim ATR. Therefore die above-mentioned assays may also be used to identify compounds d at modulate d e interaction between Rad3 and ATR where the interacting protein described in die assay methods is eitiier Rad3 or ATR. We have also shown d at Rad3 can bind to itself, strongly suggesting mat ATR can also bind to itself. Therefore the above-mentioned assays may also be used to identify compounds diat modulate Rad3-Rad3 interactions and ATR-ATR interactions. Such compounds could be used dierapeutically to disrupt ATR-ATR interactions and increase the sensitivity of mmour cells to chemotherapy and/or radiotiierapy. Thus the invention provides an assay method for screening candidate substances for anti-cancer merapy which comprises: (a) (i) incubating a polypeptide of me invention wim another polypeptide of d e invention, which may be the same as or different to d e first polypeptide, under conditions which allow die first polypeptide to bind to die second polypeptide to form a complex; (ii) bringing me complex thus formed into contact with a candidate substance; or (a) incubating a polypeptide of me invention wim anodier polypeptide of me invention, which may be the same as or different to die first polypeptide, under conditions which allow die first polypeptide to bind to me second polypeptide to form a complex and in die presence of a candidate substance; and (b) determining whether the candidate substance inhibits binding of the first polypeptide to me second polypeptide and (c) selecting a candidate substance which inhibits binding of the first polypeptide to the second polypeptide. Preferably me first and second polypeptide may be distinguished from each other. For example, the first polypeptide and die second polypeptide may both be ATR, or may bom be Rad3, or one may be ATR and one may be Rad3 or derivatives of either ATR or Rad3 which retain binding activity. When both polypeptides are ATR or Rad3, preferably two distinguishable forms of ATR/Rad3 would be used in these assays. They may be distinguished by, for example, labelling eiti er of the polypeptides. Examples of labels include radioactive labels, epitope tags or omer polypeptide tags such as glutathione -S- transferase. For example, one form of Rad3 may have one foπn of epitope tag, and d e otiier foπn would have a different epitope tag, allowing them to be distinguished immunologically such diat binding of one to me omer can be ascertained quantitively or qualitatively. In a prefeπed method, d e first polypeptide may be immobilised, for example to agarose beads or a solid support, and die second polypeptide may be in free solution. Binding is men determined using methods described above and well-known to skilled persons. Also comprehended by die present invention are antibody products (e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, CDR-grafted antibodies and d e like) and omer binding proteins (such as those identified in die assays above) which are specific for die Rad3 protein kinase domain or me Rad3/ATR lipid kinase domains. Binding proteins can be developed using isolated natural or recombinant enzymes. The binding proteins are useful, in turn, for purifying recombinant and namrally occurring enzymes and identifying cells producing such enzymes. Assays for the detection and quantification of proteins in cells and in fluids may involve a single antibody substance or multiple antibody substances in a "sandwich" assay format. The binding proteins are also manifestly useful in modulating (i.e., blocking, inhibiting, or stimulating) enzyme/substrate or enzyme/regulator interactions. Modulators of Rad3/ATR may affect its kinase activity, its localisation in the cell, and/or its interaction wim members of the cell cycle checkpoint pathway. Selective modulators may include, for example, polypeptides or peptides which specifically bind to Rad3/ATR or Rad3/ATR nucleic acid, and/or other non-peptide compounds (e.g., isolated or syntiietic organic molecules) which specifically react with Rad3/ATR or Rad3/ATR nucleic acid. Mutant forms of Rad3/ATR which affect me enzymatic activity or cellular localisation of wild-type Rad3/ATR are also contemplated by me invention. Furthermore, combinatorial libraries, peptide and peptide mimetics, defined chemical entities, oligonucleotides, and natural product libraries may be screened for activity as modulators of Rad3/ATR kinase activity and Rad3/ATR interactions in assays such as mose described above. F. Therapeutic uses Modulators of Rad3/ATR activity, including inhibitors of their lipid kinase and protein kinase activities, may be used in anti-cancer merapy. In particular, tiiey may be used to increase die susceptibility of cancer cells to chemotherapy and/or radiomerapy by virtue of tiieir ability to disrupt me cell cycle regulatory functions of Rad3/ATR. Thus the invention provides the use of compounds diat modulate Rad3/ATR activity, identified by die screening assays described above, in a method of treatment of cancer. In one embodiment, said compounds are capable of inhibiting rad3/ATR lipid kinase and/or Rad3 protein kinase activity. In another embodiment, said compounds are capable of inhibiting interactions between ATR and itself and/or between ATR and omer interacting proteins which may, for example, normally foπn part of a multimeric protein complex. It is to be understood d at d e term "compound" in this context also refers to the candidate substances selected in me above-described assays. Typically the compounds are formulated for clinical administration by mixing mem with a pharmaceutically acceptable carrier or diluent. For example they can be formulated for topical, parenteral, intravenous, intramuscular, subcutaneous, intraocular or transdermal administration. Preferably, the compound is used in an injectable form. Direct injection into the pateient's tumour is advantageous because it makes it possible to concentrate the therapeutic effect at me level of the affected tissues. It may merefore be mixed witii any vehicle which is pharmaceutically acceptable for an injectable formulation, preferably for a direct injection at die site to be treated. The pharmaceutically carrier or diluent may be, for example, sterile or isotonic solutions. The dose of compound used may be adjusted according to various parameters, especially according to d e compound used, me age, weight and condition of die patient to be treated, die mode of administration used, pad ology of die tumour and me required clinical regimen. As a guide, d e amount of compound administered by injection is suitably from 0.01 mg/kg to 30 mg/kg, preferably from 0.1 mg/kg to 10 mg/kg. The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily die optimum route of administration and dosage for any particular patient and condition. Compounds to be administered may include polypeptides or nucleic acids. The nucleic acids may encode polypeptides or they may encode antisense constructs diat inhibit expression of a cellular gene. Nucleic acids may be administered by, for example, lipofection or by viral vectors. For example, the nucleic acid may form part of a viral vector such as an adenovirus. When viral vectors are used, in general the dose administered is between IO 4 and IO 14 pfu/ml, preferably IO 6 to 10 10 pfu/ml. The term pfu ("plaque forming unit") coπesponds to die infectivity of a virus solution and is determined by infecting an appropriate cell culture and measuring, generally after 48 hours, me number of plaques of infected cells. The techniques for determining the pfu titre of a viral solution are well documented in the literature. Any cancer types may be treated by tiiese methods, for example leukaemias, and solid mmours such as breat, ovary, lung, colon, pancreas, testes, liver, brain, muscle and bone mmour. Preferably, me mmour has normal ATR function. Description of die Drawings. Figure 1 The relationship between ATR, rad3, mei-41, MEC TEL1 and ATM A. Overall structures of ATR, Rad3, Mei-41, Meclp, Tellp and ATM. Legend: open square - Rad3 domain; hatched boxes - kinase domain B. Dendrogram based on sequence alignments generated by die Clustai method (PAM250) using DNAstar software. rad3/ESRl/ mei-41 f ATR are more closely related to each otiier tiian to ATM and TELL Sequences of rad3 and ATM are available in the EMBL database. The following examples illustrate the invention. Example 1 The rad3 gene of S. pombe is one of six genes absolutely required for the DNA structure checkpoints in S. pombe (Al-Khodairy and Can, 1992; Al-Khodairy et al. 1994). A sequence representing part of the rad3 gene was reported by Seaton et al. (1992). In attempting to clarify me intron/exon structure of mis gene we identified sequencing anomalies at both the 5' and 3' ends. We have sequenced die complete gene (see Experimental Procedures) and find that rad3 is capable of encoding a product of 2386 amino acids. The C-terminal region contains die consensus sequences typical of a sub-class of kinases known as lipid kinases, the founder member of which is me pllO catalytic subunit of PI3 kinase (Hiles et al. 1992). A truncated rad3 clone lacking the amino terminus and die kinase region has been reported to complement the rad3::pR3H1.0 gene disruption mutant of rad3 (Jimenez et al. 1992). This disruption mutant does not remove the potential kinase domain. To clarify the role of this domain, we have created a null mutant by gene replacement. This mutant has amino acids 1477-2271 of rad3, including me kinase consensus domain, replaced by ura4 + . This strain, radS.d, has identical checkpoint defects and radiation/hydroxyurea sensitivities to die rad3.136 mutant (Nasim and Smith, 1975) and me original rad3::pR3H1.0 disruption mutant (Jimenez et al. 1992: Seaton et al. 1992) (data not shown). We have created three separate point mutants in die putative kinase domain of rad3 and used tiiese in gene replacement experiments to construct strains wim defined kinase null mutations. All three strains, rad3.D2230A, rad3.N2235K and rad3.D2249E have phenotypes identical to the rad3.d null mutant (data not shown), suggesting that me kinase activity is required for Rad3 function. In die light of our findings, one interpretation of the results of Seaton et al. (1992) and Jimenez et al. (1992) is that the partial clone may show intragenic complementation between the plasmid borne truncated gene and a genomic partial deletion which retains kinase function. Such an interpretation would be consistent with Rad3 acting as a dimer or multimer. When die kinase null allele rad3.D2249E was moderately over-expressed in wild type cells under control of a modified nmtl promoter (Maundrell, 1990), it caused extreme radiation sensitivity, assayed by UV strip tests, and acted as a dominant negative mutant (data not shown). When die same kinase null construct was expressed at a higher level, it inhibited growtii (data not shown). Examination of the cells indicates that division continued very slowly, and at a smaller cell size wild type cells and cells containing empty vector divide at approximately 15 microns, while rad3 and rad3.D2249E over-expressing cells divide at approximately 11.2 microns (data not shown). In S. pombe, tiiis usually indicates an advancement of mitosis. The human rad3 homolog, ATR To identify a human form of rad3, a combination of methods was applied. Through these approaches, we have cloned me entire coding region of a human gene (see materials and methods), which we have named ATR (ataxia and rad related). ATR is capable of encoding a 2644 amino acid protein which is much more closely related to d e products of S. pombe rad3, S. cerevisiae ESR1 (Kato and Ogawa, 1994) and D. melanogaster mei-41 genes (Hari et al. 1995) than to die human ATM and S. cerevisiae Tell proteins (Savitsky et al. 1995; Greenwell et al. 1995) and is likely to be die true homolog of rad3. ESR1 is allelic to the mecllsad3 checkpoint mutants (Allen et al. 1994; Weinert et al. 1994) which have an equivalent phenotype to rad3. ATR is less closely related to the human checkpoint gene ATM, containing C-terminal putative lipid kinase domain and having a similar overall structure. Sequence alignments demonstrate clearly mat the rad3lESRl(MECllSAD3)lmei-41IATR genes are more closely related to each otiier tiian any are to ATM or TELl, and diat ATM is more homologous to TELl (Figure 1). The ATM gene is expressed in a wide variety of tissues (Savitsky et al. 1995). In S. cerevisiae, ESR1 shows low level expression in mitotic cells but is rapidly induced during meiosis I (Kato and Ogawa, 1994). Using Northern blot analysis, we have demonstrated diat ATR is also weakly expressed in many tissues but diat it is more highly expressed in testis (data not shown). Given diat ATR, Rad3 and Esrlp proteins are more highly related to each otiier tiian to ATM, die higher ATR expression in testis is consistent wim the observation that Esrlp has a role in meiotic recombination (Kato and Ogawa, 1994). Using FISH and PCR analysis, we have mapped .477? to chromosome 3q22 - 3q25 (data not shown). This region is not associated wim known cancer prone syndromes. In order to further investigate die possibility that Rad3 acts as a multimer, we have created two separate tagged constructs of full length rad3 in pREP based inducible vectors. In one, Rad3 is translated witii two myc epitope tags at the N terminus, while in the o er these are substituted for a triple HA epitope tag. When botii constructs are expressed togedier in wild type cells, it is possible to co-precipitate me HA tagged Rad3 wim the myc specific antibody, and die myc tagged Rad3 witii die HA specific antibody (data not shown). This demonstrates diat, in vivo, the Rad3 protein is capable of self association and is fully consistent wim the complementation data of Jimenez et al. (1992). Almough the ATR gene could not complement the phenotype of die rad3 mutants, we have investigated die ability of ATR to form a protein complex wim S. pombe Rad3 by expressing both ATR and myc-tagged S. pombe Rad3 in the same yeast cells. Using an anti- ATR antibody (which does not precipitate S. pombe Rad3, see materials and methods) we are able to co-precipitate die yeast protein. We were also able to precipitate d e human ATR protein wim myc-specific antibodies d at recognise the S. pombe Rad3 (data not shown). These data suggest die human and yeast proteins can form a heteromeric-complex, which supports the contention, based on d e sequence similarity, of a close functional relationship between tiiese homologues. Rad3 proteins have associated kinase activity Since mutagensis experiments suggest mat d e kinase activity of the Rad3 proteins in vivo appears to be essential for their function, we have investigated mis activity further. Using S. pombe rad3::ura4 cells expressing HA tagged S. pombe Rad3, we have been able to detect a significant protein kinase activity which precipitates witii HA-specific antibodies only when Rad3 is induced and which is not changed following irradiation (data not shown). This activity, which is specific to Rad3 or co-precipitating kinase, appears to reflect phosphorylation of Rad3 itself, since die major band above 200kD that is phosphorylated can be detected by Western analysis with anti-HA antibody (data not shown). Attempts to identify convenient in vitro substrates such as myelin basic protein, RP-A and several purified S. pombe checkpoint proteins have so far proved unsuccessful. When die IP in vitro kinase assay is performed with cells over-expressing a "kinase-nuU" D2249E version of Rad3, die associated kinase activity precipitated by HA-specific antibody is significantly reduced (data not shown). There are several possible explanations for this. The measured kinase activity could reflect Rad3 activity directly. In mis case the residual activity seen with the kinase dead Rad3 could reflect die fact diat it is not unknown for the equivalent D to E mutation in other protein kinases to produce a biologically inert protein wim residual in vitro biochemical activity. Alternatively the kinase activity which phosphorylates Rad3 may be due to associated proteins, and these may interact less effectively wim the D2249E mutant protein. Discussion The checkpoint pathways controlling cell cycle progression following DNA damage or interference in the individual events which comprise the cycle are of considerable importance in maintaining genetic stability and can be considered as padiways which suppress tumorgenesis. Several mmour suppressor genes are intimately involved in subsets of the checkpoint pathways (reviewed in Hartwell and Kastan, 1994), particularly mose affecting e transition from Gl into S phase and commitment to me cell cycle. The convergence of d e two yeast model systems for checkpoints clearly indicates d at d e genes involved in diese padiways are conserved. Our work extends tiiis conservation to metazoan cells, and clarifies d e relationship between rad3, ESR1(MEC1ISAD3), mei-41 and the ATM gene. In mis work we demonstrate mat the correct sequence of the rad3 gene places its product in the family of protein/lipid kinases related to ATM. Over-expression of kinase-defective rad3 mutant in S. pombe causes a dominant negative phenotype, which suggests that Rad3 is acting as a member of a protein complex whose integrity is necessary for checkpoint function. This is consistent with die observation diat radl, rad9, rad!7, radlδ and husl deletion mutants all have phenotypes indistinguishable from rad3.d (Sheldrick and Can, 1993). Unexpectedly, unlike die remaining checkpoint rad genes, high level over-expression of either wild type or mutant τad3 alleles inhibits cell growtii and causes mitosis to occur at a reduced cell size, indicative of premature entry into mitosis. This "semi wee" phenotype is not observed in the null mutant, and may indicate interference in a second padiway whose function overlaps with diat of Rad3 and acts to inhibit mitosis. A candidate for such a padiway is die ATMITELI padiway which has been shown to have some overlapping functions wim me ESR1(MEC1/SAD1) pathway (Morrow et al., 1995). The structure of ATM is most closely related to die Tellp, which is involved in maintaining telomere lengm (Greenwell et al., 1995). However, ATM function also appears related to diat of die Rad3/Esrlp/mei-41 products. Following die initial discovery of die ATM gene and its sequence relationship to die rad3IESRl genes and to TELl, it was not clear whetiier, as in many cases in yeast, the gene had duplicated and diverged in yeast, or whether the two yeast proteins defined conserved sub-families of closely related genes. The significant finding of tiiis work is die identification of a human gene, ATR, which is more closely related to rad3IESRllmei-41. This defines two structurally distinct checkpoint related subfamilies of protein/lipid kinases that are conserved diroughout eukaryotic evolution. Altiiough die proteins in tiiese two subfamilies may have some overlapping functions, they probably control different processes. For example: the rad3 sub-family in yeast control all the Gl and G2 DNA damage checkpoints in response to both uv and ionising radiation, and the S phase checkpoint which prevents mitosis following inhibition of replication (Al-Khodairy and Can, 1992; Allen et al., 1994; Weinert et al., 1994). In contrast, A-T cells have abnormal responses to a naπow range of DNA damaging agents including ionising radiation, bleomycin and neocarzinostatin, which produce strand breaks in DNA as a consequence of radical attack. The response to uv and most chemical carcinogens is normal, as is the response to the inhibition of DNA syndiesis. It is possible diat some or all of the remaining DNA damage checkpoints and me S phase checkpoint are controlled by ATR. Experimental procedures Strains, plasmids and media Standard genetic techniques, growth conditions and media for S. pombe are described in Gutz et al. (1974). S. pombe strain spOll (ura4.D18, leul.32 ade6.704 h) has been described previously (Murray et al. 1992). Plasmid pSUB41 was a gift from S. Subramani (Seaton et al. 1992). Cloning ofS. pombe rad3 A 4.0 kb Kpnl fragment was excised from pSUB41 and sequenced in both directions to obtain the 5' rad3 sequence. The 3' clone was identified from a genomic library (Barbet et al. 1992) by colony hybridisation using a 1 kb 3' probe derived from the published rad3 sequence, and sequenced in bom directions. In tiiis way, die sequence of die entire rad3 gene was assembled. Null and "kinase dead" τad3 mutants A construct of rad3, in which die 794 amino acids between aa 1477 and aa2271 (including die kinase domain) were replaced witii a ura4+ gene, was created using the methodology described in Barbet et al. (1992). A linear fragment of tiiis was used to transform spOll to uracil prototropy and single copy integration at die radS locus was checked by Southern blotting. To create the site specific kinase null mutations, a C-terminal 3.01 kb BamHl-Saπ. fragment of rad3 was mutated witii eitiier (A: GTTTTCGCCATGGCGCGCTCCCAAACCCAA, B: TTCATCAAACAATAT I I I CGCCATGGCG, or C: CAAAAAGACAGTTGAATTCGACATGGATAG) in order to introduce eitiier the D2230A, N2235K or D2249E mutations into the kinase domain. Analogous changes have previously been used in the analysis of PI3 kinase VPS34 of S. cerevisiae (Schu et al. 1993). These fragments were then used to transform the rad3.d null mutant and gene replacements selected by their ability to grow on FOA containing media (Grimm et al. 1988). All strains were checked by Soumern blotting. Full length expression constructs of rad3.D2230A were created in pREPl and pREP41 (Maundrell, 1990) by standard subcloning following introduction of an Ndel site at me ATG and deletion of tiiree internal Ndel sites. UV radiation sensitivity strip tests Expression from REP1 (high) and REP41 (intermediate) was induced by me absence of thiamine for 18 hours prior to plating. Plates were irradiated witii a gradient of uv doses down me plate from 0 to 300 Jm '2 according to me settings on a Stratagene Stratalinker. Cloning and expression of ATR To isolate an appropriate probe for identifying cDNAs corresponding to a human rad3 homologue, degenerate oligonucleotides were designed against the amino acids LGLGDRH (5' oligo; 0DHI8) and HVDF[D/N]C (3' oligo; 0DH-I6) of Rad3/Esrlp. Inosine was incorporated at positions of four-fold degeneracy, and primers were tailed wim BamHI (0DHI8) and EcoRI (0DHI6) to facilitate cloning. DNA sequence analysis of the ~100 bp PCR product obtained from amplification of peripheral blood leukocyte cDNA demonstrated significant similarity to MECl/rad3. This sequence was used to synthesize a non-degenerate primer (oDH-23; GACGCAGAATTCACCAGTCAAAGAATCAAAGAG) for PCR with an additional degenerate primer (oDH17) designed against the amino acid sequence KFPP[I/V][L/F]Y[Q/Ε]WF of Rad3/Esrlp. The 174 bp product of this reaction was used directly to screen a macrophage cDNA library. Four positive clones were isolated (the largest approximately 3 kb). In parallel, database searches wim full lengtii S. pombe rad3 derived from the EMBL database a human cDNA clone, HSAAADPDG, as a potential homologue of rad3, if a single frameshift was allowed for in the 233 bp sequence. This 233 bp sequence is contained whhin a 1.6 kb clone obtained from Dr. N. Affara, Human Molecular Genetics Research Group, Cambridge University, UK. The entire clone (1.6 kb) was sequenced and lies within die cDNA clones identified by degenerate PCR and library screens. To identify the whole gene, RACE PCR experiments were performed on cDNA derived from placental and tiiymus mRNA using the instructions provided witii a Clontech Maratiion Kit. Gene specific primers were derived from die cDNA clones. From tiiese experiments, a 8239 bp cDNA sequence was assembled with an internal ORF of 2644 amino acids, a 79 bp 5 * noncoding region, a 194 bp 3' noncoding region and a poly A + tail. Parts of the sequence were determined solely by PCR. To avoid eπors, clones from a minimum of 3 independent PCR reactions were sequenced in both directions. The 233 bp sequence coπesponds to die sequence of nucleotides 6809 to 7042 (234 nt in total) of Seq. ID No. 1 except for a single base deletion at position 6942. This sequence encodes amino acids 2244 to 2320 of Seq. ID No. 2. The sequence ofthe "1.6 kb" insert coπesponds to nucleotides 5725 to 7104 (1353 nt) of Seq. ID No. 1, and encodes amino acids 1892 to 2340 of Seq. ID No. 2. Northern blot hybridisation: a 1.3 kb PCR product was amplified in the presence of 32 P-dCTP using primers 279-3 (TGGATGATGACAGCTGTGTC) and 279-6 (TGTAGTCGCTGCTCAATGTC). A nylon membrane containing 2 μg of size-fractionated polyA+ RNA from a variety of human tissue sources (Clontech Laboratories) was probed as recommended by the manufacturer except that the final wash was performed at 55°C rather tiian 50°C to minimize the possibility of cross- hybridisation to related sequences. Mapping ATR. We mapped the ATR gene to chromosome 3 by a combination of fluorescent in situ hybridisation and polymerase chain reaction (PCR) based assays. FISH analysis using a cDNA clone identified tiie ATR gene on chromosome 3, at approximately position q22-23. PCR analysis also identified ATR on chromosome 3. Two primers (oATR23: GACGCAGAATTCACCAGTCAAAGAATCAAAGAG and oATR26: TGGTTTCTGAGAACATTCCCTGA) which amplify a 257 bp fragment of the ATR gene were used on DNA derived from human/rodent somatic cell hybrids containing various human chromosome panels available from the NIGMS Human Genetic Mutant Cell Repository (Drwinga et al. 1993). PCR with the same primers was used to sub-localise ATR to a specific region on chromosome 3. The templates for these amplifications consisted of DNA samples from patients with truncations along chromosome 3 (Leach et al. 1994). Immunoprecipitation (IP) and kinase assays with Rad3 The S. pombe rad3 and human ATR genes were cloned into pREP41 expression vector for complementation studies. To tag d e proteins, versions of these vectors containing in- frame N terminal tag sequences, eitiier a double myc or a triple HA tag, were used (Griffiths et al. 1995). Tagged proteins were expressed by growing in media without thiamine (Maundrell. 1990). Yeast cells lysed in lysis buffer (25 mM Tris.Cl pH 7.5. 60 mM B- glycerophosphate, 0.1 mM Na 3 VO 4 , 1% Triton X-100, 50 mM MaCl, 2 mM EDTA. 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride [PMSF], 5 μg/ml leupeptin, 5 μg/ml aprotinin, 1 mM DTT) by the addition of glass beads followed by treatment in a dismembrinator for 2 minutes. For IP's 300μg total protein extract was incubated on ice with the appropriate antibody for 30 min and the immune complexes precipitated by mixing with Protein G beads for a further 30 min at 4°C. For kinase assays, the immune complexes were washed 4 timed with Lysis buffer, once with Kinase Buffer (25 mM Hepes pH7.7; 50 mM KCI; 10 mM MgCl 2 ; 0.1% NP-40; 2% glycerol; 1 mM DTT), and incubated in Kinase Buffer with 10 μM ATP [50 Ci mmol]) for 15 minutes at 30°C. The reactions were stopped with 20 ul 2X SDS sample buffer prior to separation on 6% polyacrylamide gels. Rad3 IP's contained several phosphorylated products, including one which comigrated wim Rad3 protein itself on Western analysis. References Al-Khodairy, F., and. Can, A.M. (1992). DNA repair mutants defining G2 checkpoint pathways in Schizosaccharomyces pombe. EMBO J. 11, 1343-1350. Al-Khodairy, F., Fotou, E., Sheldrick, K.S., Griffitiis, D.J.F., Lehmann, A.R. and Can, A.M. (1994). Identification and characterization of new elements involved in checkpoints and feedback controls in fission yeast. Mol. Biol. Cell 5, 147-160. Allen, J.B., Zhou, Z., Siede, W., Friedberg, E.C. and Elledge, S.J. (1994) The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. Genes Dev. 8, 2416-2428. Barbet, N.C., Muriel, W.J., and Carr, A.M. (1992) Versatile shuttle vectors and genomic libraries for use with Schizosaccharomyces pombe. Gene 114, 59-66. Beamish, H. and Lavin, M.F. (1994) Radiosensitivity in ataxia-telangiectasia: anomalies in radiation-induced cell cycle delay. Int. J. Radiat. Biol. 65, 175-184. Caπ, A.M. and Hoekstra, M.F. (1995) The Cellular Responses to DNA Damage. Trends in Cell Biology 5, 32 - 40. Chien et al., (1991) Proc. Natl. Acad Sci USA 88, 9578-9582 Deng, C, Zhang, P., Harper, J.W., Elledge, S.J. and Leder, PJ. (1995) Mice lacking p2jc iPi/ w AFi undergo normal development, but are defective in Gl checkpoint control. Cell, (in press). Drwinga, H.L., Tojia, L.H., Kim, C.H., Greene, A.E., and Mulovor, R.A. (1993). NIGMS Human/Rodent Somatic Cell Hybrid Mapping Panels 1 and 2. Genomics 16:311-314. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parson, R., Trent, J.M., Lin. D., Mercer, W.E., Kinzler, K.W. and Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumour suppression. Cell 75, 817-825 Enoch, T., Can, A.M. and Nurse, P. (1992). Fission yeast genes involved in coupling mitosis to completion of DNA-replication. Genes Dev. 6, 2035-2046. Greenwell, P.W., Kronmal, S.L., Porter, S.E., Gassenhuber, J., Obermaier, B. and Petes, T.D. (1995) TELl, a gene involved in controlling telomere length in Saccharomyces cerevisiae, is homologous to the human ataxia telangiectasia (ATM) gene. Cell submitted. Grimm, C, Kholi, J. Murray, J.M. and Maundrell, K. (1988) Genetic engineering of Schizosaccharomyces pombe: a system for gene disruption and replacement using the ura4 gene as a selectable marker. Mol. Gen. Genet. 215, 81-86. Gutz, H., Heslot, H. Leupold, U. and Loprieno, N. (1974). In "Handbook of Genetics", King R. C, Ed., Plenum Press, New York, Vol. 1, 395-446. Hari, K.L., Santene, A., Sekelsky, J.J., McKim, K.S., Boyd, IB. and Hawley. R.S. (1995) The mei-41 gene of Drosophila melanogaster is functionally homologous to the human ataxia telangiec Harper, J.W., Adami, G., Wei, N., Keyomarsi, K. and Elledge, S.J. (1993) The 21 kD Cdk interacting protein Cipl is a potent inhibitor of Gl cyclin dependent kinases. Cell 75, 805-816. Hartwell, L.H., and Kastan, M.B. (1994). Cell cycle control and Cancer. Science 266, 1821- 1828. Hiles, I.D., Otsu, M., Volinia, S., Fry, M.J., Gout, I., Dhand, R., Panayotou, G., Ruiz-Laπea, F., Thompson, A., Totty, N.F., Hsuan, J.J., Courtneidge, S.A., Parker, P.J. and Waterfield M.D. (1992) Phosphatidylinositol 3-kinase: structure and expression ofthe HOkd catalytic subunit. Cell 70, 419-429. Jimenez, G., Yucel, J., Rowley, R. and Subramani S. (1992) The rad3+ gene of Schizosaccharomyces pombe is involved in multiple checkpoint functions and in DNA repair. Proc Natl. Acad. Sci. USA 87, 4952-4956 Kato, R. and Ogawa, H. (1994) An essential gene, ESRl, is required for mitotic cell growth, DNA repair and Meiotic recombination in Saccharomyces cerevisiae. Nucleic Acids Res. 22, 3104-3112. Lamb, J.R., Petit-Frere, C, Broughton, B.C., Lehmann, A.R. and Green, M.H.L. (1989) Inhibition of DNA replication by ionizing radiation is mediated by a trans acting factor. Int. J. Radiat. Biol. 56, 125-130. Leach, R.J., Chinn, R., Reus, B.E., Hayes, S., Schantz, L., Dubois, B., Overhauser, J., Ballabio, A., Drabkin, H., Lewis, B.T., Mendgen, G., and Naylor, S.L. (1994) Regional Localisation of 188 Sequence Tagged Sites on a Somatic Cell Hybrid Mapping Panel for Human Chromosome 3 Genomics 24, 549-556 Maundrell, K. (1990). nmtl of fission yeast. A highly transcribed gene completely repressed bv thiamine. J. Biol. Chem. 265. 10857-10864. Monow, D.M., Tagle, D.A., Shiloh. Y., Collins F.S. and Hieter, P. (1995) HAT1ITEL1, a Saccharomyces cerevisiae homologue of the human gene mutated in ataxia- telangiectasia, is functionally related to the yeast checkpoint gene MEC1IESR1. Cell submitted. Murray, J.M., Doe, C. Schenk, P. Can, A.M.. Lehmann, A.R. and Watts, F.Z. (1992) Cloning and characterization of the S. pombe radl5 gene, a homologue to the S. cerevisiae RAD3 and human ERCC2 genes Nucleic Acids Res. 20, 2673-2678. Nasim, A. and Smith, B.P. (1975) Genetic control of radiation sensitivity in Schizosaccharomyces pombe. Genetics 79, 573-582. Painter, R.B. and Young, B.R. (1980) Radiosensitivity in ataxia-telangiectasia: A new explanation. Proc. Natl. Acad. Sci. USA. 77, 7315-7317 Rowley, R., Subramani, S. and Young, P.G. (1992). Checkpoint controls in Schizosaccharomyces pombe, radl. EMBO J. 11, 1335-1342. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite L., Tagle, D.A., Smith, S., Uziel, T., Sfez, S., Ashkenazi, M., Pecker, I., Frydman, M., Harnik, R., Patanjali, S.R., Simmons, A., Clines, G.A., Sartiel, A., Gatti, R.A., Chessa, L., Sanal, O., Lavine, M.F., Jaspers, N.G.J., Taylor, M.R., Arlett, C.F., Miki, T., Weissman, S.M., Lovett, M., Collins, F.S. and Shiloh, Y. (1995). A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 286, 1749-1753. Seaton, B.L., Yucel, J., Sunnerhagen P. and Subramani, S. (1992). Isolation and characterisation of the Schizosaccharomyces pombe rad3 gene which is involved in the DNA damage and DNA synthesis checkpoints. Gene 119, 83-89. Schu, P.V., Takegawa, K., Fry, M.J., Stack, J.H., Waterfield, M.D. and Emr, S.D. (1993) Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science 260, 88-91. Sheldrick, K.S. and Carr, A.M. (1993). Feedback controls and G2 checkpoints, fission yeast as a model system. BioEssays 15, 775-782. Walworm, N., Davey, S. and Beach, D. (1993). Fission yeast chkl protein kinase links the rad checkpoint pathway to cdc2. Nature 363, 368-371. Weinert, T.A., and Hartwell, L.H. (1988). The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241, 317-322. Weinert, T.A., Kiser, G.L. Hartwell, L.H. (1994). Mitotic checkpoint genes in budding yeast and die dependence of mitosis on DNA replication and repair. Genes Dev. 8, 652-665. Sequence Information. Sequence ID No. 1 : ATR seq 1 GCGCTCπCCGGCAGCGGTACGITTGGAGACGCCGGGAACCCGCGπGGCGTGGπGACTAGTGCCTCGCAGCCT 75 76 CAGCATGGGGGAACATGGCCTGGAGCTGGCπCCATGATCCCCGCCCTGCGGGAGCTGGGCAGTGCCACACCAGA 150 151 GG TAT TACAGπGTACA( WGCC (]ACAMTTCTGTGTC πCAπGACCGGATACπACA(3ATGTAAA 225 226 TGπGπGCTGTAG CπGTAMGAAMCTGACTCTCAGCC CCTCCGTGATGπGCπι3ATπCATCCAGCA 300 301 TATCATGAMTCCTCCCCACπATGTπGTAAATGTGAGTGGAAGCCATGAGCGCAAAGGCAGTTGTAπGAAπ 375 376 (^GTMπGGATCATMCGAGACπCTGCGGAπGCAGCMCTCCCTCCTGTCATπGπACACMGAAAATCTG 450 451 TG GTCATCTGπcAπAπAmcπmA 525 601 CATGAGCCGATTTπ GTCMπAGATGMCACATGGGATATπACMTCAGCTCCTTTGCAGπG^^ 675 751 GCAAGMCTCπACTπGGCAGATAGGπGTG TGCTAGAGTATGGTAGTCCAAAAAπAAATCCCTAGCAAT 825 901 GGAAπAπAAMCACCπGTAGAMTGGATACT(_AC(^^ 975 976 AMGACACTATπCCCTπGMGCAGMGCπATAGAMTAπGMCCTGTCTATπAMTATGCTGCTGGAAAA 1050 1051 ACTCTGTGTCATGTπGMGACGGTGTGCTCATGCGGCπMGTCTGATπGCTAAMGWGCTπGTGCCATπ 1125 1126 ACTGCAGTAmCCπAMTπGTGCCAGCTGGG 1200 1201 TATπGTAMGCTCTTπGGATGTGCπGGMπGAGGTAGATGCAGAGTACπGπGGGCCCACTπATGCAGC 1275 1276 mGAAMTGGAMGTATGGAMTCAHGAGGAGAnCMT^ 1350 1351 TGATGGMTATCACCCAAMGGCGTCGTCTCAGCTCGTCTCTAMCCCπCTAAMC^GCACCAAAACAGACTGA 1425 1426 GGAMπAMCATGTGCΪACATGMCCAAAAGAGCATAπATGGAGTGCACTGAAACAGAAAGCTGAATCCCπCA 1500 1501 GATTTCCCπGAATACAGTGGCCTAAAGAATCCTGπAπGAGATGπAGAAGGAAπGCTGπGTCπACAACT 1575 1576 GACTGCTCTGTGTACTGπCAπGπCTCATCAAAACATGMCTGCCGTACTπCAAGGACTGTCAACATAAATC 1650 1651 CMGMGAMCCπCTGTAGTGATMCπGGATGTCAπGGATTTπACACAA GTGCπM(^GCTGTAG G 1725 1726 TπGπAG TCTGπCAGAMCTGGACCTGGAGGCMCCATTGATMGGTGGTGAAMTπATGATGCTTTGAT 1800 1801 πATATGCMGTAMCAGπCATπGMGATCATATCCTGGAAGATTTATGTGGTATGCTCTCACπCCATGGAT 1875 1876 πAπCCCATTCTGAT(^TGGCTGTπA GπGACCACATπGCCGCTAATCπCTAACAπAAGCTGTAGGAT 1950 1951 πCAGATAGCTAπCACCACAGGCACMTCACGATGTGTGTπCTTCTGACTCTGTπCCAAGAAGAATAπCCT 2025 2026 TGAGTGGAGAACAGCAGTπACAACTGGGCCCTGCAGAGCTCCCATGAAGTAATCCGGGCTAGπGTGπAGTGG 2100 2101 ATTTTπATCπAπGCAGCAGCAGAAπcπGTAACAGAGπCCCAAGAπcπATAGATAAAGTCAAAGATGA 2175 2176 πCTGACAπGTCM( VA(W^TπGCπCTATACπGGTCMCπGTCTGTACTCπCACGGCATGTTTTATCT 2250 2251 (^CMGπCTπMCA( \CCTπCTCTGAACACGGACATGTGGACCTCπCTGTAGGAACπGAAAGCCACπC 2325 2326 TCAACATG TGTTCATCTTCTC CTAAMGCπCTGTCTGCMGCCAπCCTTπCCTACTGAAAAAAAAAAT 2400 2401 ACCTAGTCCAGTAAMCπGCTπCATAGATMTCTACATCATCTπGT GCATCπGATTπAGAGAAGATGA 2475 2476 CAGATGTAAMGCAGTTCπGGMCTπAπAMTπMTGG GATCCAGACA GATGπAGAGTGGCTπ 2550 2551 TAGTGGAMTATC GCACATAπGGMTCCπGGACTCTG GATGGATTTATAMGGAGCTTTπGTCπAAG 2625 2626 MTGMGGMGCATATACACATGCCCAMTATCMGAAATAATGAGCTGAAGGATACCπGATTCπACAACAGG 2700 2701 GGATAπGG GGGCCGCAAMGωGATπGGTACCAπTGCACTCπACACπAπGCATTGTπGπATCCAA 2775 2776 GTCAGCATCTGTCTCTGGAGCAGCATACACAGAAATTAGAGCTCTGGπGCAGCTAAAAGTGπAAACTGCAAAG 2850 2851 I I I I I ICAGCαGTAT GAMCCCATCTGTCAGTTTiTGGTAGAATCCCπCACTCTAGTCAGATGACAGCACT 2925 2926 TCCGMTACTCCATGCCA-W^TGCTGACGTGCGAAMCMGATGTGGCTCACCAGAGAGAAATGGCITTAAATAC 3000 3001 GπGTCTGA πGCCMCGTTπCGACπTCCTGATCπAATCGTTπcπACTAGGACAπACAAGπCTACT 3075 3076 ACCTGATCπGCTGCCAMGCMGCCCTGCAGCπCTGCTCTCAπCGAACTπAGGAAAACAAπAAATGTCAA 3150 3151 TCGTAGAGAGATTπ TAMCMCπCAMTATATTTTπCTCATπGGTCTGπcπGπCCAMGATGM 3225 3226 AG CGTGCCCTTCAπATCTGMGMTGAMCA(WWπGMCTGGGGAGCCTGπGAGACMGATπCCAAGG 3300 3301 AπGCATMTGMπAπGCTGCGTAπGGAGMCACTATCMCAGGTTTπMTGGTπGTCMTACπGCCTC 3375 3376 ATπGCATCCAGT(^T(3ATCCATATCAGGGCCCGAGAGATATCATATCACCTGMCTGATGGCTGAπAπTACA 3450 3451 ACCCAAATTGπGGGCATπTGGCI I I I I I lAACATGCAGπACTGAGCTCTAGTGπGGCAπGAAGATAAGAA 3525 3526 TGGCCπ(3 CAGTπ(3ATGTCTπGATGMGπMTGGGACCCAAACATGTCAGπCTGTGAGGGTGAAGAT 3600 3601 GATGACCACACTGAG CTGGCCπCGAπCMGGATGATTπCCTGAAπGTGTTGCAGAGCπGGGACTGCπ 3675 3676 TGπCGCTGCCTGGATCATGCπGTCTGGGCTCCCπCTCAGTCATGTMTAGTAGCTπGπACCTCTTATACA 3750 3751 CATCCAGCCTAMGAMCTGCAGCTATCπCCACTACCTCATMTTGAAMCAGGGATGCTGTGCMGATTπCT 3825 3901 GACCTCTGAGAGCACTGATCπCAGACMCTCπCAGCTCTCTATGMGGCCAπCMCATGAAAATGTCGATGT 3975 3976 TCGTAπCATGCTCπACMGCπG GGAMCCπGTATAAAMTCAGGAAAAACTGATAMGTATGC^CAG^ 4050 4051 CAGTGAMCAGTAGMCCTATTATCTCACAGπGGTGACAGTGCTTπGAMGGπGCCMGATGC^ 4125 4126 AGCTCGGπGCTCTGTGGGGMTGTπAGGGGMπGGGGGCGATAGATCCAGGTC(_AπAGAπTCTCAACAAC 4200 4201 TGAMCTCMGGAAMGATTπACATπGTGACTGGAGTAGMGAπCMGCTπGCCTATGGAπAπGATGGA 4275 4276 GCTAACAAGAGCπACCπGCGTATGCTGATAATAGCCGAGCTCAAGAπCAGCTGCCTATGCCAπCAGGAGTT 4350 4351 GCmCTAmATGACTGTAGAGAGATGGAGACCM∞^ 4425 4426 TGπCGGGAAATACTAGAACCTCATCTAAATACCAGATACAAGAGπCTCAGAAGTCAACCGAπGGTCTGGAGT 4500 4501 A GMGCCMTπACπMGTAMπGGGTAGT CTTTGCAGAATGGTCAGCATCπGGGCAGGπATCπAT 4575 4576 TACAMGGπCGACATGATCπGCCAGTAAMTTTTCACCTGCTGTAGCAπATGATG GCATGAπTCAAAGT 4650 4651 GACCATCTATCπcπCCACATAπCTGGTGTATGTCTTACTGGGπGTMTCMGAAGATCAGCAGGAGGTπA 4725 4726 TG GAMπATGGCAGTTCTAAAGCATGACGATCAGCATACCATAAATACCCAAGACAπGCATCTGATCTGTG 4800 4801 TC CTCAGTACACAGACTGTGHCTCCATG^^ 4875 4876 GA GCTGAGAMTGTCCACACAGCAAATCAAACAGAAATAAGGTAGACTCAATGGTATCTACTGTGGATTATGA 4950 4951 AGACTATCAGAGTGTMCCCGTTπCTAGACCTCATACCCCAGGATACTCTGGCAGTAGCπCCTTTCGCTCCAA 5025 5026 AGCATACACACGAGCTGTMTGCACTπGMTCATπAπACAGAAAAGAAGCAAAATAπCAGGAACATCπGG 5100 5101 ATTTπAWGAMπGTATGCTGCTATGCATGMCCTGATGGAGTGGCCGGAGTCAGTGCAAπAGAAAGGCAGA 5175 5176 ACCATCTCTAAAAGAACAGATCCπGAACATGAAAGCCπGGCπGCTGAGGGATGCCACTGCπGπATGACAG 5250 5251 GGCTAπCAGCTAGAACCAGACCAGATCAπCAπATCATGGTGTAGTAAAGTCCATGπAGGTCπGGTCAGCT 5325 5326 GTCTACTGnATCACTCAGGTGAATGGAGTGCATGCTAACAGGTCCGAGTGGACAGATGAATTAAACACGTACAG 5400 5401 AGTG(^GCAGCπGGAMπGTCACAGTGGGATπGGTGGAA CTAπTGGCAGCAGATGGAAAATCTACAAC 5475 5476 ATGGAGTGTCAGACTGGGACAGCTAπAπATCAGCCAAAAAMGAGATATCACAGCTTTTrATGACTCACTGAA 5550 5551 ACTAGTGAGAGCAGMCAMπGTACCTCTπCAGCTGCMGCπTGAAAGAGGCTCCTACCAACGAGGATATGA 5625 5626 ATATAπGTGAGAπGCACATGπATGTGAGπGGAGCATAGCATCAAACCACTTπCCAGCAπCTCCAGGTGA 5700 5701 CAGTTCTCAAGAAGAπCTCTAAACTGGGTAGCTCGACTAGAAATGACCCAGAAπCCTACAGAGCCAAGGAGCC 5775 5776 TATCCTGGCTCTCCGGAGGGCTπACTAAGCCTCAACAAAAGACCAGAπACAATGAAATGGπGGAGAATGCTG 5850 5851 GCTGCAGAGTGCCAGGGTAGCTAGAAAGGCTGGTCACCACCAGACAGCCTACAATGCTCTCCπAATGCAGGGGA 5925 5926 ATCACGACTCGCTGAACTGTACGTGGAAAGGGCAAAGTGGCTCTGGTCCAAGGGTGATGTTCACCAGGCACTAAT 6000 6001 TGπcπCAAAMGGTGπGMπATGTπTCCTGAAAATGAAACCCCACCTGAGGGTAAGAACATGπAATCCA 6075 6076 TGGTCGAGCTATGCTACTAGTGGGCCGATTTATGGMGA CAGCTMCTπGAAAGCAATGCAAπATGAAAAA 6150 6151 ATATMGGATGTGACCGCGTGCCTGCCAGMTGGGAGGATGGGCATTTπACCπGCCAAGTACTATGACAAAπ 6225 6226 GATGCCCATGGTCACAGACAACAAMTGGAAAAGCAAGGTGATCTCATCCGGTATATAGπcπCATπTGGCAG 6300 6301 ATCTCTACAATATGGAAATCAGπCATATATCAGTCAATGCCACGAATGπAACTCTATGGCπGAπATGGTAC 6375 6376 AMGGCATATGMTGGGAAAMGCTGGCCGCTCCGATCGTGTACAMTGAGG TGATTTGGGTAAAATAAACAA 6450 6451 GGπAT CAGAGCATACAMCTATπAGCTCCATATCMTTTπGACTGCTTTπCACMTTGATCTCTCG T 6525 6526 πGTCAπCTCACGATGMGTTTTTGπGTCπGATGGAAATMTAGCCAAAGTATπCTAGCCTATCCTCAACA 6600 6601 AGCAATGTGGATGATGACAGCTGTGTCAAAGTCATCTTATCCCATGCGTGTGAACAGATGCAAGGAAATCCTCAA 6675 6676 TAMGCTAπCATATGAAAAMTCCπA(3AG GTTTGπGGAGATGCAACTCGCCTAACAGATAAGCπCTAGA 6750 6751 AπGTGCMTA CCGGπGATGGMGTAGπCCACAπMGCATGAGCACTCATπTAAAATGCπAAAAAGCT 6825 6826 GGTAGM(^GC CATπAGTGAAATCCTCATTCCTCTACAATCAGTCATGATACCTACACπCCATCAAπCT 6900 6901 GGGTACCCATGCT CCATGCTAGCCATGMCCATπCCTGGACATTGGGCCTATAπGCAGGGTrTGATGATAT 6975 6976 GGTGGAMπcπGCπCTCπCAGAMCCA GMGATπCTπAAAAGGCTCAGATG(5AAAGTTCTACATCAT 7050 7051 GATGTGTAAGCCAAAAGATGACCTGAGAAAGGAπGTAGACTAATGGAAπCAAπCCπGAπAATAAGTGCπ 7125 7126 MGAAMGATGCAGAGTCTCGTAG GAGMCπCATAπC(W\CATATG(^GπAπCCACTAAATGATGMTG 7200 7201 TGGGAπAπGMTGGGTG CMCACTGCTGGm^ 7275 7276 GTATATGACAGGAAMGMCπCGCCAGTGTATGCTACCAMGTCAGCAGCTTTATCTGAAAAACTCAAAGTAπ 7350 7351 CCGAG TπCTCCTGCCCAGGCATCCTCCTATTTπCATGAGTGGTTTCTGAGAACAπCCCTGATCCTACATC 7425 7426 ATGGTACAGTAGTAGATCAGCπACTGCCGπCCACTGCAGTAATGTCAATGGπGGπATATTCTGGGGCπGG 7500 7501 AGACCGTCATGGTGAAMTAπCTCTπGAπCTπ(^CTGGTG TGCGTACATGTA(3ATπCMπGTCTm 7575 7576 CAATAAGGGAGAAACCiTTCAAGπCCAGAM 7650 7651 TCCTATGGGMCAGAGGGTCTTTπCG GAGCATGTGAAGπAC TGAGGCT(^TGCGTGAT(^GCG^^ 7725 7726 TπMTGAGTGTCπAMGACTTπCTACATGATCCTCπGTGGMTGGAGTAMCCAGTGAAAGGGCAπCCAA 7800 7801 AGCGCCACTGAATGAAACTGGAGAAGπGTCAATGAAAAGGCCAAGACCCATGπcπGACAπGAGCAGCGACT 7875 7876 ACAAGGTGTAATCAAGACTCGAAATAGAGTGACAGGACTGCCGπATCTAπGAAGGACATGTGCAπACCπAT 7950 7951 A(^GMGCTACTGAT(5AAAACπACTATGCCAGATGTATCπGGπGGACTCCATATATGTGAAATGAAAπAT 8025 8026 GTAAMGMTATGπMTAATCTAAAAGTAATGCATπGGTATGAATCTGTGGπGTATCTGTTCAAπCTAAAG 8100 8101 TACMCATAMTπACGπCTCAGCMCTGπATTTCTCTCTGATCAπAATTATATGTAAAATAATATACAπC 8175 8176 AGπAπMGAMTAMCTGCTπcπMTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 8239 Sequence ID No. 2 : ATR protei n 1 MGEHGLELASMIPALRELGSATPEEYNTVVQKPRQILCQFIDRILTDVNVVAVELVKKTDSQPTSV 66 67 MLLDFIQHIMKSSPL FVNVSGSHERKGSCIEFSN IITRLLRIAATPSCHLLH KICEVICSLLFLFKSKSPAI 141 142 FGVLTKELLQLFEDLVYLHRRNVMGHAVE PVVMSRFLSQLDEHMGYLQSAPLQLMSMQNLEFIEVTLLMVLTRI 216 217 IAIVFFRRQELLLWQIGCVLLEYGSPKI SLAISFLTELFQLGGLPAQPASTFFSSFLELLKHLVEMDTDQLKLY 291 292 EEPLSKLIKTLFPFEAEAYRNIEPVYLNMLLEKLCVMFEDGVLMRLKSDLLKAALCHLLQYFLKFVPAGYESALQ 366 367 VRKVYVRNICKALLDVLGIEVDAEY LGPLYAALKMESMEI IEEIQCQTQQENLSSNSDGISP RRRLSSSLNPS 441 442 KRAPKQTEEIKHVDMNQKSIL SALKQKAESLQISLEYSGLKNPVIEMLEGIAVVLQLTALCTVHCSHQNMNCRT 516 517 FKDCQHKSKKKPSVVITWMSLDFYTKVLKSCRSLLESVQKLDLEATIDKVVKIYDALIYMQVNSSFEDHILEDLC 591 592 GMLSLPWIYSHSDDGCL LπFAANLLTLSCRISDSYSPQAQSRCVFLLTLFPRRIFLEWRTAVYNWALQSSHEV 666 667 I RASCVSGFFI LLQQQNSCNRVPK I L ID V DDSD I VK EFAS I LGQL VCTLHGMFYLTSSLTEPFSEHGHVDLF 741 742 CRNLKATSQHECSSSQLKASVC PFLFLL KKIPSPVKLAFIDNLHHLCKHLDFREDETDVKAVLGTLLNLMEDP 816 817 DKDVRVAFSGNIKHILESLDSEDGFIKELFVLRMKEAYTHAQISRNNELKDTLILπGDIGRAAKGDLVPFALLH 891 892 LLHCLLSKSASVSGAAYTEIRALVAAKSVKLQSFFSQYKKPICQFLVESLHSSQMTALPNTPCQNADVRKQDVAH 966 967 QREMALNTLSEIANVFDFPDLNRFLTRTLQVLLPDLAAKASPAASALIRTLGKQLNVNRREILINNFKYIFSHLV 1041 1042 CSCSKDELERALHYLKNETEIELGSLLRQDFQGLHNELLLRIGEHYQQVFNGLSILASRASSDDPYQGPRDI ISP 1116 1117 EL ADYLQPKLLG I LAFFNMQLLSSS G I EDKKMALNSLMSLMKLMGPKH SSVRVK MHLRTGLRF DDFPEL 1191 1192 CCRAWDCFVRCLDHACLGSLLSHVIVALLPLIHIQPKETAAIFHYLIIENRDAVQDFLHEIYFLPDHPELKKIKA 1266 1267 VLQEYRKETSESTDLQTTLQLSMKAIQHENVDVRIHALTSLKETLYKNQEKLIKYATDSETVEPI ISQLVTVLLK 1341 1342 GCQDANSQARLLCGECLGELGAIDPGRLDFSπETQGKDFTFVTGVEDSSFAYGLLMELTRAYLAYADNSRAQDS 1416 1417 AAYAIQELLSIYDCREMETNGPGHQL RRFPEHVREILEPHLNTRYKSSOKSTDWSGVKKPIYLSKLGSNFAE S 1491 1492 AS AGYLITKVRHDLASKIFTCCSIMMKHDFKVTIYLLPHILVYVLLGCNOEDOQEVYAEIMAVLKHDDQHTINT 1566 1567 QDIASDLCQLSTQTVFSMLDHLTQWARHKFQALKAEKCPHS SNRN VDSMVSTVDYEDYQSVTRFLDLIPQDTL 1641 1642 AVASFRSKAYTRAVMHFESFITEKKQNIQEHLGFLQKLYAAMHEPDGVAGVSAIRKAEPSLKEQILEHESLGLLR 1716 1717 DATACYDRAIQLEPDQI IHYHGVVKSMLGLGQLSTVITQVNGVHANRSEWTDELNTYRVEAA KLSQ DLVENYL 1791 1792 AADGKSTT SVRLGQLLLSAK RDITAFYDSLKLVRAEQIVPLSAASFERGSYQRGYEYIVRLHMLCELEHSI P 1866 1867 LFQHSPGDSSQEDSLNWVARLEMTQNSYRAKEP I LALRRALLSLNKRPDYNEMVGECWLQSARVARKAGHHQTAY 1941 1942 NALLNAGESRLAELYVERAK LWSKGDVHQALIVLQKGVELCFPENETPPEG NMLIHGRAMLLVGRFMEETANF 1016 2017 ESNAIMKKY DVTACLPE EDGHFYLA YYDKLMPMVTDNKMEKQGDLIRYIVLHFGRSLQYGNQFIYQSMPRML 2091 2092 TLWLDYGTKAYEWEKAGRSDRVQMRNDLGKINKVITEHTNYLAPYQFLTAFSQLISRICHSHDEVFVVLMEI IAK 2166 2167 VFLAYPQQAMWMMTAVSKSSYPMRVNRC EILNKAIHMKKSLE FVGDATRLTDKLLELCN PVDGSSSTLSMST 2241 2242 HFKML LVEEATFSEILIPLQSVMIPTLPSILGTHANHASHEPFPGH AYIAGFDDMVEILASLQ P KISLKG 2316 2317 SDGKFYIMMCKPKDDLRKDCRLMEFNSLINKCLRKDAESRRRELHIRTYAVIPLNDECGIIEWVNNTAGLRPILT 2391 2392 KLYKEKGVYMTGKELRQCHLPKSAALSEKLKVFREFLLPRHPPIFHEWFLRTFPDPTSWYSSRSAYCRSTAVMSM 2466 2467 VGYILGLGDRHGENILFDSLTGECVHVDFNCLFNKGETFEVPEIVPFRLTHNMVNGMGPHGTEGLFRRACEVTMR 2541 2542 LMRDQREPLMSVLKTFLHDPLVEWSKPVKGHSKAPLNETGEVVNE A THVLDIEQRLQGVIKTRNRVTGLPLSI 2616 2617 EGHVHYLIQEATDENLLCQMYLGWTPYM 2664 Sequence ID No. 3: rad3.seq 1 ∞TACC^GTAAAAACTGCπAGTAAGTATAAAACACAGAAGAATCCGCGATCTAGTGAACCAATGCCCTGCGTA 75 76 TGACGCTC CTGACGCTATAGTCMTGAGMCTAGGATGTGCGAπATMCπATCTTπC TATTπcπAT 150 151 TATTTATπM( \AT πGMπAAAACTCATπcπCTTπAπAGCCGTAAMTAGCπATπTCTCTCCT 225 226 ACTACCTTΓCAACAATAAC I 1 1 1 1 1 1 1 1 IGTrTAπGACCAπATAATCACATCAAAAGTCAAAAAAπCAATCA 300 301 πATCAGAAACATCCAGCCT TAπACπAA GπAGTTTCCTCTGAAAAπCAGTATCACAAAAGCTCGπA 375 376 AπAGCATCGCTCCΪATACπAGTGCACCATGWTCπCCTπACCTCGTGAGTGGAAATCGATπGATAATCGAT 450 526 CGCGCGTGπGCGTTTTAAAAAGGCCI I I I I I IGAAπGAATCAATGGTrTGATATAGTATGAGCCAACACGCAA 600 601 AMGGAMGCTGGGTCACTC(^TCTπCACCCAGAGGCπAGATGACAGACAGGCTπCGGACAGCTTTTGAAAG 675 676 AAGTAπAGCAπAGACAAAGAACATGAGπAGGTAGAAGTAAπcπTACCATCTATGACCTCCGAGCπGπG 750 751 GTTπMπG GπGGTCπCTAGCTTπA CATGATGAπCAAAATCTGAATπATCTCTCCTAAGATGC 825 826 TAAMG GCCCATCTCTCTCTACMGCGπ TGCTMTCπAAAAAGGTCTCCGACAGππGCGGGAGAπA 900 901 MTCATCTGπACTCTTπGGAπGGATTrTACCCAGGACTATATCAπGTπGCTGATAπCGTπTAπAAGT 975 976 TATπGACTCAπAAMGAGTπCATMGCTMTπATCAGCTAATCAGTGAAAAGTCAπCCTATGGGACπAT 1050 1051 ATGCπCGTrTATGCGπAπGGAAATAπATAπACAAACGTπcπCTATAGTTCTCCAAATCACTAATGCTA 1125 1126 CAπCCCπACAAGATGCCCTCACCCAAπCTCAACCAπGCAGAGTATCTCCCCAAATTATCCAACCCATCGAG 1200 1201 AGGACAMTπGATπACπATCAπMTATA( G(-AGGCπGTACATTπTCTTTGAAAGTGCCCAI 1 1 1 1 1 IG 1275 1276 CACMTGCTCATATπAMGA TCC TTπCCTAGTCCACCTCTCTrTACAGCGTGGACπGGATCAAGCCAT 1350 1351 Gl 1 1 1 1 1 I TTπGπATTπAπAAAACGAATCAGCATCGGAGACTCACAGCTCTTrCTACATπGCAπCAC 1425 1426 GTATAGTCCAMCTπATGCTGTTTπCCπGMTim-ATATATCATGGCCπCCCATπGTGAAAAATCTAAAC 1500 1501 ATATπTAATGTCCTCCATCAACπAACAπGGGATCAπGAAGAAAACTTATACAGπGCTAATACTGCTATAT 1575 1576 CTC 1 1 1 1 1 1 1 ICTCTCTπATπGTTπACCCAAAACTGTAGCTGGTCTAπCTATCCTTπGGGG ' πTCCπAC 1650 1651 TTTCTGACπC GGTAπACWGCAACπGAACCAGAπCTGATCTCAAAAAGGCAATAATAπATπAAGTGCA 1725 1726 GATACCAMGπCAGA TAGATCA CMCTCTCCGTGCππGGCGAMTπGTACTGGTAAACTTGAAAACA 1800 1801 CGπGTTπCTMCTCTGMπAMCCTTTπCTπTACAπATCTπCCπGGACAATGACπGTCAAATAπC 1875 1876 πA GTGGATπCCAGMTGGTCATAACATATGTACATTTGCAAAATGGTGTATAAACAACAACπAGATGAAC 1950 1951 CGTCTMTπAAAGCACTiTCGTGAAATGπAGAπAπATAGCTCTCATAATGπACAATAAGTGAGGACGACC 2025 2026 TG GMCπCTCTTrAGTπTGTGTACTCATGπGCAAAGGTGAATGAGAAAACAAATAGTATTπCCGCACAT 2100 2101 ATGMGTACATGGπGTG GTπGTMCTCATTπGTπACTATπGATGAGCGGTCGCCTTFTAAAAπCCπ 2175 2176 ATCACGAAπGTTπGTGCAπGCTAAAAAATCCCGACATAATπCCTCπCTGπAAACAATCAπGπGCπG 2250 SLIS 5VV31V33V51V3U93XLXV311131V3WDW1WU3331111 IW311W313111V133WV1331V3W IQLS 00 LS 3939W31 V3331931331 W3V333V33V3V1 W3W39V13333WV1 V3VJ11 V991 W33VW31331 V33 9Z9S SZ9S 31W3U333V3VW3JJiVV31331VVVVVV93131VlVV3W33nV9V93131VlVlVV^ ISSS ςt OSSS V33V3WW3111 VVWV31 V1333113V113V313V33131331 WV33V33W3U VW1333V1333133V1 9LPS S PS 3W333VU333313333311311311 VI V31131 W3V333111311 W333V313VW313311 V33V13VU I OPS OOPS 13V31 WU W333V33133W131 V±LLL VI V31 U311 V31 V1333V311 V3339333V3V3WV3311 W3 9Z£S SZΣS 3V3V1331331 V31133V1311333W33133333V333V311 W31331111311 V33W933V133V1 W33V ISZS OSZS 1U1V1V33V1333UVW133W33U131W33U3W33VVWV3U131313WWWU33UV3UV13 9LIS Ofr SLIS 1V1333U33331V3U33W3UV1333U1VWU31V3W33UV13V33V33W3V31W31W1V11U3 ΪOΪS OOTS UV3VUL3V3U 3U3131VV31VUV3333331VV331331V33V3WU33JJ13331WVV3333VWV 9Z0S SZOS V1VWV31331V33WW3UVUVUWV33VU3U3V3JJ1333313V3331V3VV33V3UVWV31V3V1 IS6P 0S6P 1U3313W3W31V3 13313VUV31O3JJ1VW1U31313V33VV331VW31V3V331V31V3UVV3 9L8P SL8P 31331V1V1VW33V3311 3V3V1VUV33313V3VU133V331V1V33133V3V1331W133V1V3V3W I08P C£ 008P 33V333UV11U3UV331331331V31UV3313UVWU131313UV133VUV3VVWV3U33 1V3 9ZLP SZLP 313U131UV313V3U3WW3131V331V31VV3V3313133V1331V3W331333131V1VU333VV3V IS9P 0S9P 3VW33W33UV33313U33V3V1V333UVV33V3VV3VVV3331V333U3331VW3W 33VUV331 9LSP SLSP 3UV3WUJJJ1V131V3V13J 1V3133V3V1V3VW3VV333331333UWVUV331V3133V33333W 10SP OOSP 31WUVU3U33V33UW3W3UV313WV1WU3W3313W3V313V333WUUVU31VWUU 9ZPP 0£ 5ZPP 3U31U333U3U3UU31333UV3WU53V3W33V3WV313V13WV33U3UJ.V133U1V1VW ΪS€P OS£P VW31333VWV333UV33333V13V331V3UVWU313UJL13U3V331V33U3V1V3UV13VU31V 9LZP SLZP VW3VW1V1UV1333V1333UV3V3UVWV33331VV33V3W1 V31V13W33U3WUU1V33V1 IOZP OOZP VU3313133VVV331VU1V313331 3131V33UV3VV3V3W1331313W13V333VVVWWV1WU 9ZΪP SZIP V313V333313W3UV33133U33WV13JJLL3V3W33131331V1333U3U 33W3V33WV13V1V ISOP ςz OSOP 313V13VU3U331U33V33UWU3V3331VV331VUUV3V13UVU13VV3U13WV3VV3V333V 9L6 S£6£ VVV31U3Wl\ιVU3U3 3 WV3WVUVUVlOVV31333VV33333333V3331V3VlV33dl3331 106Z 006£ lM133U31VWWV33133U31VlV31VlVW331Vim3VV3U331VlVmi313U3UWllU 9Z8Z SZB€ 3331V3W13VUW33V3313U3W33W331V1V3V33U1WV13V3V3V31V3VU3V33V33133W33 ISL£ OSL£ 3VΩUU1U13VV3VUVVWV3VU133V1 VU31U3V333V31VVW33W13WU1313WUW1 9L9ε 03 SL9 V13VW3U33V31313V111UV3VV31VVW3U333U313UV1VVV3WV1333WU333V11133133 I09ε 009£ 3V3UW3JJldv 3V33331V1333313VWUV33V V133313W3V3V3 V313U31UVllUV3U 9ZSε SZS£ 1V1VW3UW13V133V3V33VV3VV3Ω3VV3V1 VU333UV1U33133VIU1W13U313WU13 ISPε OSPC 3133UW3U3VlV13V33333V33VV33VV33VUVlV3JJd3V3U33U33VW31VV331VlU133Wl 9L££ 00££ U31VU31VWWV3UΩ33313UmV3WUV3VVmiWUm 9zzε SZZε 331V1W131U1W3V33VU31V13391111V3V31W1WI IIIII IV31V1 3V11W33W1W33V31 ISK OSiε 13V3m3 WU3313mi31313U m3V133Vmwm331WVV3UVVVVVV31V3133U 9L08 sioε 3immmv 33WU3U3mi3i3vuvi3 vi 3im i333vu3 3i33Wjjιv3iι rooε 000£ 3VWVV3U W13U3v 33313V31U3U3U331V31313V3V3VV33l W1331V31V333V13VU 9Z6Z 01 SZ6Z 3V1333U33U331VVW1V331V1VO3VU33313U13V133U31V313WV3V311L3VV3133V1V13 IS8Z 0S8Z 3V13V1WU333WV3VVVW13VU3V13U33UV33VU13V3V13333V3V3VV33UV11311UV333 9LLZ SLLZ 33V333J±LVlVV31VU33V31331UVU13V333VlV3VV333WVVW13331V133W3313UV33dU ΪOLZ QQLZ 3331313V3W3333UV1V3313J113VUW3331 3331V1V1V313333V331333UWV3W331313 9Z9Z SZ9Z 333V313133UV333VΩ1VUUV1VV3333V3WV1V31313U31V1VU3VV33UV13V13UUV3V1 ISSZ c OSSZ immmmV13313W131VU3313i i33m3UV31333VWV]±UV133V3VlVWV331 9LPZ SLPZ 33333UV1WW31133V1WI 111 IV3U333WV13VW33W3V311LW3U3V1V1V31131W1W13 IOPZ OOPZ Jt 9Wiitα_J__irø339JJ-U9WW39139n 92ε2 92ε2 192 - εf - Z,6lZ0/96aθ/13d OP60/L6 OΛV 5776 MCCTAAAMTCGTAMG cmAGGmTCCACπ GGA GTGπCπGAMCπACAAAATGGC 5850 5851 TCGGAAMGCTGGCCMCTGGGAπGMGGATπGGAGACGTAπAT TAAAGCGGTAGAGATπA^ 5925 5926 GTGAGMTACGCAπAπATCπGGCCATCATCGAGTπTMTGTATGMGMGMCAAMGCTCCCAGπAATG 6000 6001 AACAGAGCGAACGATTTπMGTGGTGAGπAGTAACTCGCΛTAAπMCGAATπGGTCGATCT^^ 6075 6076 GTAC TCATATATATG GTATGCCAAMπGCTCACACTGTGGCπGAT GGGGCC (^AACπCGCT 6150 6151 TATCTAAAGATGACGGCGAAAAGTACTπCGTGAACACΑπATCTCπCGAGAAAAAAAT^ 6225 6226 AπCGAATGπTGTCGCCTπCTATGAAAAπCCTCAATACπrπTCTGGπGCAπATCCCAAATGATATCCA 6300 6301 GAGTATGCCATCCAAATAATAMGTπATAAMlTnGGAACATATAAπGCAAACGπGTAGi^^^ 6375 6376 GGGAGACGCTATGGCMπMTGG(MCMTAAMTCGACπCTCAAMGCGCTCGCπCGTGGAAAMG(A 6450 6451 TAMTGTπTACAπCTAGGMGCTπCTATGTCπCCAMGπGATATAAMGCACTCAGTCMTCTG(MπC 6525 6526 TC πACTGA Gπ CAA GTGmT CM(mπ AmT TCTGT AmTGAGCπ GGAK 6600 6601 ATTπCGGCTπCTTrTGATGATCCGGTAGAlTrAGTCAπCCTGCTA TCATTTπAG^^ 6675 6676 CTAMGATGCT CAGAGCTAGTCAπATC ^ 6750 6751 TGGATATAATGAACTCTCπCAAAAACCAAGAAAAGTGTACGπAGAGGTACGGATGGCAACTTATACCCAπCT 6825 6826 TGTGCAMCCCAAAGATGATCπCGTMGGATGCTA(^πGATGGMTπMTMTCπATπGTAAAATAπGA 6900 6901 GGAMGATCMGMGCG CAG GGMCπGTGTAπAGMCπATGπGπAπCCTTTAAATGAAGAATGCG 6975 6976 GAmATCGMTGGGTA TCATACTCGTCCAmAGA 7050 7051 CCATATCATATCMGAMTCAMGTTGATTTAGACTπG(^CTGCG GTCCTMCCCTGGTGATATATrT(^ 7125 7126 AGAAAATCπACCGAMTπCCTCWGTTTTTTATGAGTGGπTGπGMTCTπCCCAGMCC^ 7200 7201 πACTAGTAGACAAMCTAπGCCGMCπTAGWGT TGTCMTAGπGGCTACGTTπGGGTπGGGAGATC 7275 7276 GCCATGGCGAAMCATAπGTπGATG TTrACAGGTG GCTATCCATGTCGATπCMCTGTCTTTTTGATA 7350 7351 MGGTCπACTπTGAAAAACCTGAAMGGTGCCGπCAGAπMCTWTMTATGGTAGATGCMTGGGTCCGA 7425 7426 CAGGπATGMGG(KGTπCAGGAMGCTAGCGAMT C(^TGCGGCTTCTTCGCTCAAACCAAGATACAπGA 7500 7501 TGAGCGTACTAGAGTCTπCCTACATGATCCπTAGTCGAGTGGAATAGAAAGAAGTCGTCAAGCAAGTACCCGA 7575 7576 ATMTGMGCAMTGMGTmGGATATMπCGC^AAM 7650 7651 TATCTAπGMGGGCAAAπCAAGAAπGATCAAATCTGCTGTCAACCCAAAAAACCTGGTAGAAATGTACAπG 7725 7726 GπGGGCTGCπATπCTAGCATTπACT C W πTCAATGAACAAGCTACCCAπAπAAACTTATGAπ 7800 7801 TG TCGMGATATTπATπAπMTCCGATGMG πCTCGCTGAGπGπCMTπCπGTMTTπCCTT 7875 7876 CCATπCTAMTCGTCGAπCGCπAMTAGGGCACTGGCTTTπGTGCATTTrTCTCTCGTAAAGCAGCπCTG 7950 7951 AnGAAAAAMGCTATATCTGTnCTGAGTCATCATCCGMTCMCAATATATTTTGCAGATCGACCTGCAG 8022 In italics, sequenced by Seaton et al . In Bold are those bases deleted in Seaton et al . (2499. 22501. 2507. 2509) Underlined are the two bases either side of a single C insert (5918/5919) in Seaton et al . (i .e. the incorrect base not shown, but the one residue either side is) Sequence ID No. 4 : rad3 protein 1 MSQHA R AGSLDLSPRGLDDRQAFGQLL EVLALDKEHELGRSNSLPSMTSELVEVLIEVGLLAFKHDDS SEF 75 76 ISPKMLKEAHLSLQALMLILKRSPTVLREIKSSVTLLDWILPRTISLFADIRFIKLFDSLKEFHKLIYQLISEKS 150 151 FLWDLYASFMRYWKYYITNVSSI VLQITNATFPYKMPSPNSQPLQSISPNYPTHRED FDLLI INIEEACTFFFE 225 226 SAHFFAQCSYLKKSNFPSPPLFTAWTWI KPCFFNF I LLKR I S IGDSQLFLHLHSRI VQTLCCFSLNF I YHGLP I 300 301 CEKSKHILMSSINLTLGSLKKTYTVANTAISLFFLSLFVLPKTVAGLFYPFGVSLLSDF VLEQLEPDSDLKKAI 375 376 ILFKCRYQSSEIDQπLRAFGEICTGKLENTLFSNSELNLFLLHYLSLDNDLSNILKVDFQNGHNICTFAKWCIN 450 451 NNLDEPSNL HFREMLDYYSSHNVTISEDDLKNFSLVLCTHVAKVNEKTNSIFRTYEVHGCEVCNSFCLLFDERS 525 526 PFKIPYHELFCALLKNPDI ISSSVKQSLLLDGFFRWSQHCSNFNKESMLSLREFIMKALASTSRCLRVVAAKVLP 600 601 IFIKGPNNLDIVEFHKESKALIFNTLKILAVENTAILETVILS ISLSRVVEEEELHFVLLEVISSVINSGIFYQ 675 676 GIGLSALQQIASTRHISVWQLLSPYWPTVSVAIVQGMGK^^ 750 751 KALIVRIAELSQSDVATLCLTNMHKILASLLTTDHPNLEESVMLLLSLATSDFEKVDLTSLLRSDPISITVELLQ 825 826 L YQNDVPHEKIENALRKVAMIVSQVVNDEDLSNKELL YDFFNNHILGILAEFSNILN3LKGKTSINEKIKTIVGI 900 901 EKMLSLCGGAVKLGLPQILSNLOSAFQNEHLRFYAIKAUFSLILATKEPEYSSIAGLSLVILPPLFPYLEPQEAE 975 976 L VIQIFDFISSDTHKCLQGLKUAIPTSLDSACFSLKAKEIFCSLQNEDFYSELQSIIKCLTNENEPVCYLGLQKL 1050 1051 ELFFQAKVDELHDTLNLDISNEVLDQLLRCLLDCCVKYASTNMQISYLAAKNLGELGAIDPSRAKAQHUKETVV 1125 1126 LDNFENGEESLKFILDFMQSQLIPAFLVTWTKAQGFLAYALQEFLKLGGFKSAVINKKKGLTVVTEHUMSLPDL 1200 1201 SKRVLIPFLTSKYHLTPIPKIDIRYPIYKENVTIHTmQLFSLKLΗEYAHSQmEKIFGICSKVVKDQEVNIPCF 1275 1276 LLPFLVLmLTESELEVNKVIEEFQLVINQPGPDGLNSVGQQRYTSFVDVFFKIVDYLNKULRMRKKRNUDRRS 1350 1351 AIARKENRYMSVEDATSRESSISKVESFLSRFPSKTLGIVSLNCGFHARALFYUEQHIRNATAPYAALESDYRVL 1425 1426 QEIYAGIDDPDEIEAVSLNFHDYSFDQQLLLHENSGTWSALSCYEIIIQKDPENKKAKIGLLNSMLQSGHYESL 1500 1501 VLSLDSFIINDNHEYSKMLNLGIEASmSLSIDSLKKCLSKSNLESFEAKLGSIFYQYLRKDSFAELTERLQPLY 1575 1576 VDAATAIANTGAHSAYDCYDILSKLHAINDFSRIAETDGIVSDNLDIVLRRRLSQVAPYGKFKHQILSTHL VGYE 1650 1651 KFENTKKTAEIYLEIARlSRKmQFQ iLK OLDKPLATIE QmiHQGQHR SELNFSLm^ 1725 1726 VDEHEERPKmETLGNPLKGKVFLKLTKULGMGQLGLKDLETYYHW^ 1800 1801 LPVNEQSERFLSGELVTRI INEFGRSLYYGTNHI YESMPKLLTLWLDFGAEELRLSKDDGEKYFREHI ISSRKK 1875 1876 SLELMNSNVCRLSMKIPQYFFLVALSQMISRVCHPNNKVYKILEHI IAN VASYPGETLWQLMATIKSTSQKRSL 1950 1951 RGKS I LNVLHSRKLSMSSKVDI KALSQSAI L ITEKL I NLCNTRI NSKSVKMSLKDHFRLSFDDPVDLV I PAKSFL 2025 2026 DITLPAKDANRASHYPFPKTQPTLLKFEDEVDIMNSLQ PRKVYVRGTDGNLYPFLCKPKDDLRKDARLMEFNNL 2100 2101 ICKILRKDQEANRRNLCIRTYVVIPLNEECGFIEWVNHTRPFREILLKSYRQKNIPISYQEIKVDLDFALRSPNP 2175 2176 GDIFEKKILP FPPVFYEWFVESFPEPNNWVTSRQNYCRTLAV SIVGYVLGLGDRHGENILFDEFTGEAIHVDF 2250 2251 NCLFDKGLTFE PEKVPFRLTHNMVDAMGPTGYEGGFRKASE ITMRLLRSNQDTLMSVLESFLHDPLVEWNRKKS 2325 2326 SSKYPNNEANEVLDI IR KFQGFMPGETIPLSIEGQIQELIKSAVNPKNLVEMYIGWAAYF 2386

Claims: CLAIMS 1. A polynucleotide in substantially isolated form capable of hybridising selectively to Seq.ID No. 1 or to its complement. 2. A polynucleotide according to claim 1 which comprises of Seq.ID No. 1 or a fragment thereof. 3. A polynucleotide probe which comprises a fragment of at least 15 nucleotides of a polynucleotide as defined in claim 1 or 2. 4. A polynucleotide in substantially isolated form comprising Seq.ID No. 3 or its complement. 5. A polypeptide in substantially isolated form which comprises either of the sequences set out in Seq ID Nos. 2 or 4 polypeptide substantially homologous thereto, or a fragment of the polypeptide of Seq. ID No. 2. 6. A polynucleotide in substantially isolated form encoding a polypeptide according to claim 5. 7. A vector carrying a polynucleotide as defined in claim 1, 2 or 6. 8. An antibody capable of binding die polypeptide of Seq. ID. No. 2 or fragment thereof. 9. A method for detecting die presence or absence of a polynucleotide as defmed in claim 1 in a human or animal body sample which comprises: bringing a human or animal body sample containing DNA or RNA into contact with a probe comprising a polynucleotide or primer as defined in claim 1 under hybridizing conditions; and detecting any duplex formed between the probe and nucleic acid in the sample. 10. A method of detecting polypeptides as defined in claim 6 present in biological samples which comprises: (a) providing an antibody according to claim 7; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed. 11. An assay method for screening candidate substances for anti-cancer d erapy which comprises: (a) providing a polypeptide of the invention which retains lipid kinase activity and a substrate for said kinase, under conditions and witii reagents such diat the kinase activity will act upon the substrate; (b) bringing said polypeptide and substrate into contact with a candidate substance; (c) measuring the degree of decrease in the kinase activity of the polypeptide; and (d) selecting a candidate substance which provides a decrease in activity. 12. An assay method for screening candidate substances for anti-cancer therapy which comprises: (a) (i) incubating a polypeptide of the invention with another as polypeptide of die invention, which may be the same or different to the first polypeptide, under conditions which allow the first polypeptide to bind to die second polypeptide to form a complex; (ii) bringing the complex thus fonned into contact with a candidate substance; or (a) incubating a polypeptide of die invention witii another polypeptide of d e invention, which may be the same as or different to die first polypeptide, under conditions which allow the first polypeptide to bind to die second polypeptide to form a complex and in the presence of a candidate substance; and (b) determining whetiier the candidate substance inhibits binding of d e first polypeptide to the second polypeptide and (c) selecting a candidate substance which inhibits binding of die first polypeptide to the second polypeptide. 13. A method according to claim 12 wherein said first polypeptide can be distinguished from said second polypeptide. 14. A method of treating cancer in a patient which comprises administering to said patient a therapeutically effective amount of a candidate substance selected according to the method of any one of claims 11 to 13. 15. A method of increasing the susceptibility of cancer cells in a patient to chemotherapy and/or radiotherapy which comprises admimstering to said patient a therapeutically effective amount of a candidate substance selected according to die method of any one of claims 11 to 13. 16. Use of a candidate substance selected according to the method of any one of claims 11 to 13 for the treatment of cancer. 17. Use of a candidate substance selected according to die method of any one of claims 11 to 13 for increasing the susceptibility of cancer cells to chemotiierapy and/or radiotherapy.

Inventors: CARR ANTONY MICHAEL, CARR, ANTONY, MICHAEL
Applicants: CARR ANTONY MICHAEL, MEDICAL RES COUNCIL, CARR, ANTONY, MICHAEL, MEDICAL RESEARCH COUNCIL
Application year: 1996
Main classification: C12N15
IPC codes: A61K38, A61K39, A61K48, C07K14, C07K16, C12N1, C12N9, C12N15, C12Q1, G01N33